The esophageal epithelium in systemic sclerosis: cellular and molecular dysregulation revealed by single-cell RNA sequencing

- 3
- 4 Matthew Dapas¹, Margarette H. Clevenger², Hadijat M. Makinde¹, Tyler Therron¹, Dustin A.
- 5 Carlson², Mary Carns¹, Kathleen Aren¹, Cenfu Wei², Lutfiyya N. Muhammad³, Carrie L.
- 6 Richardson¹, John E. Pandolfino², Harris R. Perlman^{1*}, Deborah R. Winter^{1*}, Marie-Pier
 7 Tetreault^{2*}
- 8
- 9

10 A	ffiliations
------	-------------

- Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of
 Medicine, Chicago, IL
- Division of Gastroenterology & Hepatology, Department of Medicine, Northwestern University
 Feinberg School of Medicine, Chicago, IL
- 15 3. Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago,
- 16

IL

- 17
- 18
- 19
- 20 *These authors jointly supervised the work
- 21

22 ABSTRACT

23

24 Systemic sclerosis (SSc) is a rare autoimmune disease characterized by vasculopathy and progressive 25 fibrosis of the skin and internal organs. Individuals with SSc often suffer from chronic acid reflux and 26 dysphagia due to loss of esophageal motility. However, the pathogenesis of esophageal dysmotility in SSc 27 is poorly understood. To determine whether distinct changes in esophageal epithelial cells contribute to 28 impaired motility in SSc, we investigated the stratified squamous esophageal epithelium using single-cell 29 RNA sequencing (n=306,372 cells) in individuals with SSc compared those with gastroesophageal reflux 30 disease (GERD) as well as healthy controls. The proportion of epithelial cells in the outermost, superficial 31 compartment of the esophageal epithelium was significantly reduced in SSc (9.4% vs 21.6% in HCs). 32 Differential gene expression in SSc was primarily limited to the superficial compartment (3,572 genes vs. 33 232 in all other compartments), with significant upregulation of extracellular matrix and keratinization 34 genes. These cellular and molecular changes in SSc were highly correlated with those seen in GERD, 35 indicating they were secondary to reflux; however, their magnitudes were more pronounced in the proximal 36 esophagus, suggesting that esophageal dysmotility leads to greater proximal acid exposure, which may 37 contribute to aspiration. SSc-specific gene dysregulation implicated immunoregulatory pathways likely 38 pertinent to pathogenic mechanisms. By offering a comprehensive view of transcriptional dysregulation at 39 single-cell resolution in human esophageal epithelial cells in SSc compared to GERD and healthy tissue, 40 this work clarifies the state of epithelial cells in SSc-induced esophageal dysfunction.

41 INTRODUCTION

Systemic sclerosis (SSc), also known as scleroderma, is an immune-mediated rheumatic disease of 42 43 unknown etiology that causes progressive fibrosis of the skin and internal organs. Although uncommon (18-26 per 100,000 people)¹⁻⁴, SSc is one of the deadliest autoimmune disorders⁵, with a 10-year survival 44 45 rate of 45-68% following diagnosis^{4,6,7}. Over 90% of individuals with SSc report gastrointestinal (GI) 46 dysfunction⁸, with esophageal dysmotility being the most common GI manifestation⁹. Individuals with SSc 47 and esophageal involvement typically suffer from chronic acid reflux and dysphagia due to loss of esophageal motility and are at much greater risk of esophageal stricture and Barrett's esophagus^{8,10,11}. The 48 49 rate of esophageal involvement was nearly twice as high in individuals with SSc who died within 5 years 50 of diagnosis¹².

51 There are multiple, interrelated mechanisms that may cause esophageal dysmotility in SSc. 52 Vascular damage and neurogenic impairment lead to smooth muscle cell fibrosis¹³, but esophageal muscle 53 atrophy has also been observed in SSc without vasculopathy or fibrosis¹⁴. Inflammatory signatures¹⁵, 54 absence of anti-centromere antibodies¹⁶, and presence of anti-topoisomerase I antibodies are associated with 55 esophageal complications, as well⁸. Complicating research efforts is significant clinical and molecular heterogeneity observed between SSc patients¹⁷⁻¹⁹ and difficulty distinguishing between effects from 56 57 autoimmune processes and secondary factors such as severe reflux. Consequently, the pathogenesis of 58 esophageal disease in SSc remains poorly understood.

Molecular investigations of SSc esophageal involvement have primarily focused on canonical pathways in submucosal and muscle layers²⁰. However, the mucosa is no less essential for normal esophageal transport^{21,22}, and recent studies have suggested that esophageal epithelial cells (EECs) may play a more central role in the pathogenesis of SSc esophageal involvement than previously thought²⁰. Mouse models with epithelial-cell-specific knockout of *Fli1*, an Ets transcription factor implicated in SSc pathogenesis²³, spontaneously develop dermal and esophageal fibrosis and interstitial lung disease²⁴. Importantly, the resultant lung disease is mediated by T-cell autoimmunity, but fibrosis of the skin and

esophagus persist in mice additionally lacking mature T and B cells, suggesting that the fibrosis is
 principally driven by the epithelia^{20,24}.

68 Most studies implicating epithelial cells in SSc esophageal dysmotility have been performed in mice or *in vitro*, and molecular analyses in humans have so far been limited to bulk tissues¹⁵. Furthermore, 69 70 single-cell gene expression studies performed in other diseases of the esophagus, including squamous cell carcinoma^{25,26} and allergic eosinophilic esophagitis^{27,28}, have identified substantial cellular and molecular 71 72 changes in EECs compared to healthy tissue, such as significant expansion of non-proliferative suprabasal cells^{27,28}. Therefore, to comprehensively investigate the effects of SSc on the esophageal epithelium, we 73 74 performed single-cell RNA sequencing (scRNA-seq) of esophageal mucosal biopsies from SSc patients 75 with clinically significant esophageal involvement and compared EEC distributions and gene expression 76 signatures to individuals with gastroesophageal reflux disease (GERD) and healthy controls (HCs). By 77 examining gene expression profiles from human tissue at single-cell resolution, this work sheds essential 78 light on the cellular roots of esophageal dysfunction in SSc by clarifying the pathogenic role of the 79 squamous epithelium, one of the most integral tissues supporting healthy esophageal function.

80

81 METHODS

82

83 Subjects

84 The SSc study population were recruited from adult patients aged 18 to 89 diagnosed with SSc according 85 to the 2013 ACR/EULAR classification criteria, who visited the Northwestern Medicine Esophageal Center for esophageal symptom evaluation and motility testing, as described previously²⁹, between 2020 and 2021. 86 Patients with GERD were recruited at the primary visit following positive Bravo pH testing²⁸. Patients with 87 88 technically inadequate panometry or manometry studies, previous foregut surgeries (including prior 89 pneumatic dilation), or mechanical obstructions in the esophagus such as esophageal stricture, eosinophilic 90 esophagitis, severe reflux esophagitis (Los Angeles classification C or D), or hiatal hernias larger than 5 91 cm were excluded. HCs met asymptomatic criteria including lack of esophageal symptoms, no history of

alcohol dependency or tobacco use, body mass index less than 30kg/m², and no previous antacid or proton
 pump inhibitor treatment²⁸. The study protocol received approval from the Northwestern University
 Institutional Review Board.

95

96 Symptom evaluation and motility testing

97 Esophageal function testing included functional lumen imaging probe (FLIP) panometry during sedated 98 endoscopy, high-resolution manometry (HRM), and in some subjects, 24-hour pH-impedance or timed-99 barium esophagram, which were completed and interpreted as previously described³⁰⁻³³. HRM 100 classifications were based on the application of the Chicago Classification v4.0 to 10 supine and 5 upright 101 test swallows³⁴. FLIP panometry classifications were based on previous evaluation of asymptomatic 102 volunteers and patients³⁵⁻³⁷. During endoscopy (same encounter as HRM/FLIP), esophageal mucosal 103 biopsies were obtained at approximately 5-cm ("distal esophagus") and 15-cm ("proximal esophagus") 104 proximal to the squamocolumnar junction. Acid exposure was measured as the percentage of time with 105 esophageal pH<4 over a monitoring period of 24 hours. Most patients also completed validated symptom-106 questionnaires (patient-reported outcomes) on the day of esophageal motility testing with FLIP or HRM, 107 including the Brief Esophageal Dysphagia Questionnaire (BEDQ), the Gastroesophageal Reflux Disease 108 Ouestionnaire (GerdO), and the Northwestern esophageal quality of life (NEOOL) survey.³⁸⁻⁴⁰.

109

110 Sample processing and sequencing

Esophageal mucosal biopsies from proximal and distal esophagus were processed for scRNA-seq as described in Clevenger et al²⁸. Briefly, following tissue digestion and filtering, cell suspensions met 85% minimum viability via Cellometer Auto2000 (Nexcelom Bioscience). Cells were loaded into a Chromium iX controller (10X Genomics) on a Chromium Next GEM Chip G (10X Genomics) to capture approximately 10,000 cells per sample and were processed for encapsulation following the manufacturer's protocol. Cell barcoding and library construction were performed using the 10X Genomics Chromium Next GEM Single Cell 3' Reagents Kits v3.1 and Dual Index Kit TT Set A according to the manufacturer's

protocol. Sequencing was performed by the NUseq Core using the Illumina Novaseq 6000. Paired-end reads consisting of a 28-base-pair read for cell barcodes and unique molecular identifiers and a 90-basepair read for transcripts were aligned to the GRCh38 reference transcriptome using Cell Ranger v6.1.2.

121

122 Sample and cell quality control

123 Samples with high ambient RNA (<70% of sequencing reads mapped to cells) were removed from 124 consideration. Gene expression counts generated by Cell Ranger were analyzed using Seurat v4.3.0⁴¹. Cells 125 with low gene diversity (<200 unique genes), low unique molecular identifier counts (<500), or excessive 126 counts (>100,000) were removed from consideration. Cells with high proportions of mitochondrial DNA 127 reads, indicative of apoptosis or lysis, were removed using the bivariate regression models implemented in 128 the miQC package⁴². Cells were filtered if their proportion of reads mapped to mitochondrial DNA 129 exceeded 0.05 and their posterior probability of belonging to a compromised cell distribution was greater 130 than 0.75 according to miQC. Doublets, in which more than one cell is clumped together in a single droplet, 131 were predicted and removed using scDblFinder⁴³ with an expected, additive doublet rate of 0.01 per 132 thousand cells with standard deviation of 0.01.

133

134 Sample integration and cell type annotation

135 Individual samples were normalized and integrated on 3,000 variable features using Seurat's SCTransform procedure⁴⁴ with v2 regularization⁴⁵ and canonical correlation analysis dimension reduction. Integration 136 137 anchors were determined using a reference consisting of three pairs of proximal and distal samples from 138 HCs. Principal component (PC) analysis was performed on the transformed and integrated expression 139 counts. Uniform manifold approximation and projection (UMAP)⁴⁶ embeddings were calculated on the top 140 40 PCs with n=200 neighbors. Cell clustering was performed using Seurat's modularity-based clustering 141 on a shared nearest neighbor (SNN) graph with k=25 on the top 40 PCs. Clusters were annotated according 142 to the expression of established cell-specific gene markers (Supplemental Table 1, Supplemental Figure

143 1). For annotation of smaller cell clusters, we first filtered out the epithelial, myeloid, lymphoid, and 144 endothelial cell clusters and then recomputed PCs and re-clustered the subset (PCs = 25, k=15).

145

146 Epithelial cell characterization

147 After isolating the subset of epithelial cell clusters, we further filtered cells with disproportionately low 148 read counts (<3,500; Supplemental Figure 2, A-C). The samples were then re-integrated using the 149 procedure described above. UMAP embeddings were calculated on the top 35 PCs with n=100 neighbors. 150 Epithelial compartments (basal, suprabasal, and superficial) were identified according to expression of 151 established markers (Supplemental Figure 4D)^{27,28,47-50}. For each compartment, we computed composite 152 gene signature scores using Seurat's AddModuleScore() function (Supplemental Figure 2E). Cells were 153 initially clustered on an SNN graph with k=50 with resolution=0.25 (Supplemental Figure 2F), but 154 because the modularity optimization clustering implemented in Seurat grouped proliferating cells across 155 different epithelial compartments and inconsistently distinguished suprabasal and superficial cells, we 156 applied K-means clustering on the expression of the compartment-specific markers to delineate epithelial 157 compartments. We performed separate K=2 K-means clustering on 1) the Seurat clusters containing basal 158 and early suprabasal cells (clusters 1-5) to distinguish basal from suprabasal compartments and 2) the Seurat 159 clusters containing late suprabasal and superficial cells (clusters 6-8) to demarcate suprabasal and 160 superficial compartments (Supplemental Figure 2, G-H). Proliferating epithelial cells were identified 161 using Seurat's CellCycleScoring() function. Cells predicted as being in S or G2/M phases based on the relative expression of corresponding markers⁵¹ were labeled as proliferating cells (Supplemental Figure 162 163 21). We tested for statistical differences in proportions of epithelial cell populations between conditions using MASC⁵². To derive a continuous epithelial differentiation score for each cell (Supplemental Figure 164 165 3), we combined the compartment-specific module scores as follows :

- 166 $EDS_{C} = score_{suprabasal} + score_{superficial} score_{basal}$
- 167

168 Where EDS_C is the epithelial differentiation score for a given cell. This EDS_C was then scaled between 0

169 and 1:

170

171
$$EDS_{C,scaled} = \frac{EDS_{C} - \min(EDS_{1}, \dots, EDS_{n})}{\max(EDS_{1}, \dots, EDS_{n}) - \min(EDS_{1}, \dots, EDS_{n})}$$

172

173 Gene expression analysis

To identify dysregulated pathways in SSc, we first calculated differential gene expression between conditions within each epithelial compartment, considering each cell as a sample. Differential gene expression was calculated using the FindMarkers() function in Seurat with the Wilcoxon rank-sum test on log-normalized RNA counts for genes expressed in at least 1% of cells by compartment. We adjusted for multiple testing using a Bonferroni correction accounting for the number of genes tested. Genes with an adjusted P<0.05 and absolute log₂ fold change >0.1 were considered significantly differentially expressed. 53,54 Genes were then ranked by the magnitude and statistical certainty of their expression differences:

181

182
$$Weight = -\log_{10}(p) * abs(\log_2[FC])$$

183

Gene set enrichment was calculated using 3,795 canonical pathway gene sets from the Human Molecular Signatures Database⁵⁵ using gene set enrichment analysis (GSEA)^{53,54}. Statistical gene set enrichment was calculated using one-way positive enrichment with 100,000 permutations on pathways with at least 10 genes. Mitochondrial and ribosomal genes were excluded from the GSEA.

To more robustly characterize gene expression differences between conditions⁵⁶, we performed pseudo-bulk differential expression analysis by aggregating RNA counts per sample within epithelial compartments. Genes with at least one count per million detected in at least 75% of samples in at least one condition per epithelial compartment were analyzed. To mitigate outlier-driven signals, genes with logtransformed expression greater than 3 standard deviations from the mean in exactly one individual were

excluded. Differential gene expression was evaluated using edgeR v3.42.4⁵⁷⁻⁵⁹. Gene expression was modeled using a quasi-likelihood negative binomial generalized linear model, with global negativebinomial trended dispersion estimated across all samples and gene-specific quasi-likelihood dispersions estimated within each epithelial compartment. Differences in gene expression across conditions were assessed using quasi-likelihood F-tests with false-discovery rate (FDR) adjustment. We conducted tests combining both proximal and distal esophageal regions, as well as separate tests for each esophageal region.

199 Transcription factor enrichment analyses were conducted on the pseudo-bulk results using the enricher() function from clusterProfiler v4.8.3⁶⁰. We used consensus results from ENCODE⁶¹ and ChEA⁶², 200 201 as curated by the Ma'ayan Lab⁶³ and available at http://amp.pharm.mssm.edu/Enrichr/⁶⁴to test for the 202 enrichment of transcription factor target genes from among genes that were differentially expressed 203 between SSc, GERD, and HCs with Bonferroni-adjusted p<0.05. Background gene sets were comprised of 204 the genes included in the pseudo-bulk differential expression analyses for each epithelial compartment. 205 Transcription factors absent from the background gene set were removed as candidate transcription factors. 206 Separate enrichment tests were performed for all differentially expressed genes (DEGs) and those that were 207 upregulated or downregulated in SSc. Enrichment results were adjusted using a Bonferroni correction 208 accounting for the number of transcription factors with more than 2 genes in the significant DEG list .

209

210 Pseudo-bulk sample permutation

Because of the sample size imbalance by disease state, which inherently yields different statistical power for different tests across conditions, we permuted differential expression testing with equivalent sample sizes to better evaluate the relative extent of dysregulation by EEC compartment and biopsy location between SSc and GERD. We permuted all possible combinations of SSc samples with sample size n=4 for both the proximal and distal regions and used the median statistics in the SSc vs. HCs tests to more directly compare the results with those observed in GERD vs. HCs.

217

218 Gene expression trajectory analysis

219 To model gene expression as a continuous function along the axis of epithelial cell differentiation, we 220 utilized the framework implemented in Lamian⁶⁵, with the epithelial differentiation score serving as the 221 underlying pseudotime metric. Lamian fits a polynomial B-spline curve with the number of knots 222 determined by minimization of the Bayesian Information Criterion. With few cells near the lower and upper 223 limits of our epithelial differentiation score and the interpolation range bound by the minimum and 224 maximum pseudotime values, the B-spline models produced erratic fits near the interpolation boundaries. 225 Therefore, we instead modeled natural cubic splines, which are constrained to linearity at the boundaries 226 (second derivative is zero), and we excluded the lowest and highest 1% of cells from the interpolation 227 interval. Using these modeled gene expression trajectories, we performed hierarchical clustering of 228 differential gene trajectories for all genes that were significantly differentially expressed between SSc and 229 HC in single-cell-level differential expression testing.

230

231 Clinical phenotype associations

232 To test for associations with categorical measures of esophageal function (FLIP, HRM, NM), we performed 233 ordinal logistic regression that modeled likelihoods of increasing clinical severity. We excluded individuals 234 with achalasia or esophagogastric junction outflow obstruction (EGJOO) from ordinal regression modeling 235 motility. For FLIP we combined the "borderline/diminished" and "impaired/disordered" phenotypes. For 236 NM we combined the Stage I and Stage II ineffective motility phenotypes. The resultant ordering for the 237 ordinal regression was "normal"< "ineffective" < "absent" for HRM; "normal" < "borderline/diminished 238 & impaired/disordered" < "absent" for FLIP; and "normal" < "stages I & II - ineffective" < "stage III -239 absent" for NM.

For association testing with quantitative clinical measures in SSc, we first performed a principal components analysis (PCA) on a set of nine quantitative clinical traits: HRM mean distal contractile interval (DCI), HRM basal esophagogastric junction (EGJ) pressure, HRM EGJ contractile index, HRM median integrated relaxation pressure (IRP), FLIP intra-balloon pressure at 60ml, FLIP EGJ distensibility index, the GerdQ impact score, the BEDQ score, and the NEQOL score. Missing values were imputed with the

245 mean. We then modeled associations with the first two PCs using linear regression. Gene expression was
246 represented using log-transformed counts.

- 247
- 248
- 249 **RESULTS**

250 Whole tissue single-cell RNA sequencing (scRNA-seq) was performed on paired proximal and distal 251 mucosal biopsies from ten patients with systemic sclerosis (SSc), four with gastroesophageal reflux disease 252 (GERD), and six healthy controls (HCs). All participants but one in each group were female (Table 1). SSc 253 patients were significantly older than HCs (54.9 vs 27.0 years; P<0.001). Among SSc patients, six had the 254 limited cutaneous subtype, three had the diffuse cutaneous subtype, and one had sine scleroderma with no 255 cutaneous symptoms (Supplemental Table 1). Mean SSc disease duration at the time of biopsy was 132 256 months. All SSc patients had positive serum antinuclear antibody and impaired esophageal motility. 257 Following sample-level quality control (Supplemental Table 2), 39 samples were retained for analysis, 258 including 19 from the proximal esophagus and 20 from the distal esophagus.

259

260 Characterization of esophageal mucosal cell populations

A total of 306,372 esophageal cells (7,856 mean cells per sample) were retained for cell clustering and gene expression analysis (**Figure 1**). Each cell type was identified according to the expression of established cell-specific gene markers including *KRT6A*, *KRT13*, and *KRT15* for epithelial cells (**Supplemental Table 3**, **Supplemental Figure 1**). Epithelial cells comprised the bulk of the sample (n=264,858; 86.45%), followed by lymphoid cells (n=25,129; 8.20%), myeloid cells (n=10,019; 3.27%), endothelial cells (n=4,027; 1.31%), and all other cell types (n=2,339; 0.76%).

267

268 Significant loss of superficial EECs in SSc

269 Following isolation of the epithelial cell cluster and additional quality control (Supplemental Figure 2, A-

270 C), we characterized the remaining 230,720 esophageal epithelial cells (EECs) according to their

271 differentiation and cell cycling states (Figure 2A). We classified the EECs into five primary compartments: 272 basal (n=55,818; 24%), proliferating basal (n=36,439; 16%), proliferating suprabasal (n=25,314; 11%), 273 suprabasal (n=82.283; 36%), and superficial (n=30,866; 13%) based on relative expression of canonical 274 epithelial genes and cell cycle markers (Figure 2, B-C; Supplemental Figure 2, D-E). Roughly 40% of 275 basal cells and 24% of suprabasal cells were proliferating, and the fractions of cells that were proliferating 276 did not differ by disease (Figure 2D; Supplemental Figure 2, F-I). Proportions of basal and suprabasal 277 cells were not significantly different across conditions, but there were significantly fewer superficial cells 278 in SSc compared to HCs (μ_{SSc} =0.10, μ_{HC} =0.21, P=0.003, Figure 2E). The reduction of superficial cells in 279 SSc was further apparent when examining EEC differentiation score distributions (Supplemental Figure 280 3) and projecting UMAP embeddings separately by disease state (Figure 3).

281

282 EEC gene dysregulation highly correlated in SSc and GERD, limited to superficial cells

283 Overall, the gene expression correlation between biopsy locations was extremely high, ranging from r=0.98 284 to r=0.99 for the 2,000 most variable genes (Supplemental Figure 4A) aggregated by condition and 285 epithelial compartment (Supplemental Figure 4B; Supplemental Table 4). Inter-sample expression 286 correlations indicated that the greatest gene expression heterogeneity was in the superficial compartment 287 (mean=0.94, std. dev.=0.027), followed by the basal compartment (mean=0.94, std. dev.=0.018; Figure 4, 288 A-B). Differential gene expression between conditions was most predominant in the superficial 289 compartment (Figure 4, C-E). At the single-cell level, about 6.6% and 4.1% of expressed genes were 290 significantly differentially expressed between SSc and HCs in the superficial compartment in the proximal 291 and distal regions, respectively, compared to just 1.3-1.4% and 1.3-3.0% in non-proliferating basal and 292 suprabasal cells (Supplemental Tables 5-6). Most differentially expressed genes (DEGs) were only 293 differentially expressed in one epithelial compartment (Figure 4, C-D). We observed more suprabasal 294 differential expression in the distal esophagus than in the proximal esophagus for both SSc and GERD 295 (Figure 4, C-E). Many of the same genes were significantly dysregulated in both SSc and GERD compared 296 to HCs (Supplemental Table 5). Depending on the compartment and biopsy location, 22-44% of

297 significantly dysregulated genes in SSc or GERD were differentially expressed in both conditions (Figure 298 4E). Consequently, the DEGs in SSc and GERD were significantly enriched for some of the same pathways, 299 particularly those related to the extracellular matrix and keratinization (Figure 4F). Clustered trajectories 300 of relative gene expression (SSc vs. HCs) by epithelial differentiation score for all single-cell-level DEGs 301 revealed distinct patterns of differential expression (Figure 4, G-H), which were principally distinguished 302 by the direction of gene expression change in superficial cells. Gene expression changes were more 303 pronounced in the most terminally differentiated superficial cells in the proximal esophagus (Figure 4G), 304 whereas in the distal esophagus the differences appeared more in late-stage suprabasal and early-stage 305 superficial cells (Figure 4H).

306 Six pathways were significantly enriched among DEGs between SSc and HCs: matrisome 307 (suprabasal, distal $P_{FDR}=2.3\times10^{-4}$, Figure 4H; superficial, distal $P_{FDR}=2.6\times10^{-2}$) and matrisome-associated 308 genes (suprabasal, distal $P_{FDR}=4.4\times10^{-4}$); cornified envelope formation (suprabasal, distal $P_{FDR}=2.1\times10^{-3}$; 309 superficial, distal P_{FDR} =4.7×10⁻²), and keratinization genes (suprabasal, distal P_{FDR} =2.1×10⁻³; superficial, 310 distal $P_{FDR}=5.0\times10^{-2}$; developmental biology-related genes (suprabasal, distal $P_{FDR}=4.1\times10^{-4}$; superficial, distal $P_{FDR}=9.2\times10^{-3}$); and innate immune system genes ($P_{FDR}=2.8\times10^{-2}$, Figure 4G). No pathways were 311 312 significantly enriched among genes differentially expressed between SSc and GERD in any epithelial 313 compartment. The leading edges of significantly enriched pathways (Supplemental Table 7) contained 314 recurring genes from shared protein families, including serine protease inhibitors (serpins, Supplemental 315 Figure 4C), keratins (Supplemental Figure 4D), S100 proteins (Supplemental Figure 4E), and small 316 proline-rich proteins (SPRRs, Supplemental Figure 4F). The most frequent gene in leading edges of 317 significantly enriched pathways was PI3 (Supplemental Figure 4G), including all pathways enriched in 318 SSc. Among the other most enriched pathways specific to SSc were those related to the regulation of metal 319 and immune homeostasis (Figure 4F, Supplemental Table 7).

Upon aggregating single-cell expression counts by sample for each EEC compartment, we found that gene expression patterns clustered by EEC compartment (**Supplemental Figure 5A**) and that differential expression between conditions was nearly exclusively limited to superficial cells (**Figure 5**, A-

B; Supplemental Figure 5B). There were 3,572 genes differentially expressed between SSc and HCs with
FDR q<0.05 in the superficial compartment, compared to just 232 total in all other compartments, including
only 172 that were not also differentially expressed in the superficial compartment (Supplemental Table
8). The differential expression observed in SSc was again highly correlated with the changes seen in GERD
(Figure 5, C-D). The correlations in log₂ fold change between SSc and GERD vs. HCs were consistently
between 0.40-0.53 in all compartments except for superficial cells, where we observed much stronger
correlation in the proximal region (r=0.82) than in the distal region (r=0.36; Supplemental Figure 5C).

330 We detected 2,103 genes that were significantly differentially expressed in SSc but not GERD in 331 the proximal esophagus and 282 in the distal esophagus, of which 170 were differentially expressed only 332 in the distal region (Figure 5, C-D; Supplemental Table 9). Among the most upregulated SSc-specific 333 genes (Figure 5, C-E; Supplemental Figure 5, C-D) were genes related to inflammation (PTGES, 334 *MFGE8*)^{66,67}, innate immune response (*FCGBP*, *BST2*, *CD44*, *APOBEC3A*)⁶⁸⁻⁷¹, immune cell migration 335 (C10orf99, LTB4R, ACKR3)⁷²⁻⁷⁴, antigen presentation (HLA-B, CD74, TAP1, PSMB8, PSMB9)⁷⁵, natural killer cell activation (*CLEC2B*)⁷⁶, and fibroproliferation (*SGK1*, *HBEGF*)^{77,78}. Four of the top five and eight 336 337 of the top 20 most downregulated SSc-specific genes by fold change in superficial EECs in the proximal 338 esophagus were metallothioneins (MT1A, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, MT2A). The 339 metallothioneins comprised the bulk of three pathways uniquely enriched in SSc with P<0.001: zinc 340 homeostasis, copper homeostasis, and cellular responses to stimuli (Figure 4F). The most down-regulated 341 SSc-specific gene across both the proximal and distal esophagus was the H19 lncRNA. Interestingly, the 342 most down-regulated gene by fold change in GERD, MUC22, was not differentially expressed in SSc. One 343 gene, SLC8A1-AS1, was significantly differentially expressed in both GERD and SSc, but in opposite 344 directions (Figure 5, C-E; Supplemental Table 9).

More genes were significantly differentially expressed in SSc than in GERD, but in terms of relative fold change vs. HCs, we observed greater expression changes in GERD (**Supplemental Figure 5C**). We therefore performed all possible sample permutations with equal numbers of SSc and GERD samples (n=4) and repeated differential gene expression testing to more directly compare the relative

349 number of DEGs in both conditions (Figure 5F). In superficial cells from the proximal esophagus, there 350 were more DEGs in SSc in 60% of permutations, but the relative FC differences were greater in GERD in 351 61% of permutations (Supplemental Table 10). In the distal region, there were more DEGs in GERD in 352 62% of permutations, and the relative FC differences were greater in GERD in all permutations. The 353 correlations between SSc and GERD in terms of relative gene expression changes were consistently much 354 higher in the proximal region permutations than in the distal region (Figure 5, G-H). The permutation 355 results confirmed that the differences in gene expression observed in SSc relative to GERD were not simply 356 due to differences in sample size.

In summary, the gene expression changes measured in SSc and GERD were highly correlated. In the distal esophagus, differential expression was more pronounced in GERD than in SSc, whereas in the proximal esophagus there were more DEGs in SSc. In both conditions, differential gene expression was most prevalent in the superficial compartment, but the expression changes appeared comparatively earlier in the differentiation of distal EECs relative to proximal EECs.

362

363 Transcription factor enrichment analysis

364 We next examined whether DEGs in SSc superficial cells were significantly enriched for targets of specific 365 transcription factors. Among genes differentially expressed in SSc compared to GERD, the target genes of 366 IRF1 were significantly enriched (Table 2). IRF1 targets were significantly enriched among all proximal 367 superficial DEGs ($p_{adi}=0.021$) and among only those that were downregulated ($p_{adi}=0.0024$). However, 368 *IRF1* was not itself differentially expressed in superficial cells in SSc compared to GERD. Compared to 369 HCs, three transcription factors were significantly enriched in SSc in the proximal esophagus, including 370 MYC ($p_{adi}=2.1\times10^{-7}$) and E2F4 ($p_{adi}=5.5\times10^{-5}$) for upregulated DEGs and NFE2L2 for downregulated 371 DEGs ($p_{adi}=7.6\times10^{-4}$). MYC and E2F4 were also themselves differentially expressed in SSc compared to HCs in superficial cells ($p_{adj}=7.8\times10^{-5}$, $p_{adj}=9.8\times10^{-4}$, respectively). MYC was the most enriched 372 373 transcription factor in genes upregulated in GERD compared to HCs, but the enrichment was not significant

after adjusting for multiple testing (p_{adj}=0.11). No transcription factors were significantly enriched in any
 pairwise comparison in the distal esophagus.

376

377 Expression mapping in superficial EECs

378 Examining the expression patterns within superficial cells from the proximal esophagus more closely, we 379 identified five distinct clusters (Figure 6A) distinguished by unique expression marker patterns (Figure 380 6B, Supplemental Figure 6, Supplemental Table 11) and varying degrees of differentiation (Figure 6C). 381 Clusters 1 and 3 represent the outermost, terminally differentiated epithelial layers, as evidenced by their 382 FLG expression⁷⁹⁻⁸¹. They differed by the expression of metallothioneins, which were predominantly 383 expressed in cluster 3 (Figure 6, E-F). Cluster 3 was less abundant in SSc compared to HC with P<0.05 384 (Figure 6D), but metallothionein expression was lower in other superficial clusters, as well (Figure 6F). 385 Within the superficial EECs, the relative expression of metallothioneins was significantly correlated with the differentiation score (r=0.06, P= 2.3×10^{-23}). Cluster 2 was distinguished by its relatively high CTSV 386 387 expression. Clusters 4 and 5 were the least differentiated of the superficial cells and were distinguished by 388 their relative expression of GJB6 and FGFBP1, respectively, although neither gene was differentially 389 expressed between conditions.

For the expression of the significantly enriched transcription factors (IRF1, MYC, E2F4, and NFE2L2; **Table 2**) and their targets, we observed two consistent patterns (**Figure 7**). First, the greatest magnitude differences in median target expression between SSc and HCs were seen in cluster 5. Second, in each of those instances, the median target expression in GERD was between that of SSc and HCs. The expression correlations between the enriched transcription factors and their targets were positive for *MYC* (r=0.42) and *E2F4* (r=0.24) and negative for *IRF1* (r=-0.20) and *NFE2L2* (r=-0.18).

396

397 FLI1 expression in human EECs

398 Deletion of the *Fli1* gene in epithelial cells in mice has been shown to recapitulate histological and 399 molecular features of esophageal involvement in SSc^{24} . Therefore, we investigated the expression of *FLI1*

400 in our human esophageal samples. The expression of *FL11* in human EECs was negligible and did not meet 401 the minimum expression thresholds for inclusion in our differential gene expression analysis. We did 402 observe low FLI1 expression levels in endothelial cells (Supplemental Figure 7A), but the expression 403 differences between SSc, HCs, and GERD was not significant (Supplemental Figure 7B). There were 404 many FLI1 downstream targets among the proximal, superficial DEGs between SSc and HCs and seven 405 between SSc and GERD (ARPC2, RAB24, MTPN, PPIF upregulated; CEBPZ, TRMT10C, TBP 406 downregulated); however, the proportion of these genes among all DEGs was not different than what would 407 be expected by chance (P>0.05), and the average expression of FL11 targets was higher in GERD and lower 408 in HCs compared to the expression in SSc (Supplemental Figure 7C).

409

410 Correlations with clinical phenotypes

411 We next evaluated whether the cellular and molecular changes we observed between SSc, GERD, and HCs 412 were correlated with specific clinical measures of esophageal dysfunction (Table 1). To test for associations 413 with esophageal motility phenotypes, we performed ordinal regression against increasing phenotype 414 severity. To more efficiently model the covariance structure among quantitative, functional esophageal 415 measures in SSc (Figure 8A), we performed PCA on a set of nine clinical metrics and tested for correlations 416 with the first two PCs (Figure 8B). The first PC explained 45.5% of variance and was most correlated with 417 FLIP intra-balloon pressure at 60ml (r=0.94), The second PC explained 22.6% of variance and was most 418 correlated with HRM basal EGJ pressure (r=0.74).

We did not observe any significant correlations between epithelial cell compartment proportions in SSc and esophageal motility phenotypes. It appeared that the low proportion of superficial cells in the esophageal epithelium was a universal feature in SSc, regardless of phenotype (**Supplemental Figure 8A**). The proportion of superficial cells decreased with disease duration, but the trend was not statistically significant (P=0.1; **Supplemental Figure 8B**). We also did not observe any significant correlations between EEC compartment proportions and quantitative trait PCs (**Figure 8C**).

425 We then tested for correlations with gene expression in superficial EECs for genes that were 426 significantly differentially expressed in SSc compared to HCs ($P_{adj} < 0.05$) and nominally differentially 427 expressed in SSc compared to GERD (P<0.05). There were 433 genes that met these criteria in the proximal 428 esophagus and 99 in the distal esophagus. Although no associations with esophageal motility phenotypes 429 were statistically significant after adjusting for multiple testing, the strongest phenotypic correlation was 430 with *TRIM11* (P_{FLP}=0.01, P_{HRM}=0.007, **Supplemental Figure 8C**), a gene recently found to attenuate Treg 431 cell differentiation in CD4⁺ T cells in mice⁸². No associations with the top two clinical PCs were significant 432 after adjusting for multiple testing. We also tested for clinical PC correlations with aggregate 433 metallothionein gene expression and transcription factor target expression for IRF1, MYC, E2F4, and 434 NFE2L2. We observed one nominal association between the mean metallothionein module score and PC1 435 (P=0.02, Figure 8D). Notably, within superficial cells we also observed a strong correlation between the 436 proportion of metallothionein-expressing cluster 3 cells and PC1 in the distal esophagus (Figure 8E). This 437 indicates that not only is this population of cells reduced in SSc, but its relative decrease is further correlated 438 with more severe esophageal involvement (Figure 8F). Therefore, our findings suggest that increased 439 esophageal dysmotility in SSc is associated with a decline in metallothionein-expressing superficial EECs, 440 which coincides with lower overall metallothionein expression in superficial cells.

441

442

443 **DISCUSSION**

Esophageal dysfunction is extremely common in SSc and is significantly associated with increased mortality and lower quality of life^{83,84}. The causal mechanisms by which SSc affects the esophagus, however, have not been conclusively determined. Here, we sought to clarify the role of epithelial cells in SSc esophageal dysfunction by using scRNA-seq to quantify cellular and transcriptional changes relative to HCs and individuals with GERD. While our findings indicate that epithelial changes in SSc result primarily from chronic acid exposure, they also highlight immunoregulatory pathways uniquely altered in SSc that may be linked to pathogenic aberrations.

451 With epithelial layers of the skin and internal organs being primary sites of injury in SSc, the 452 pathogenic role of epithelial cells in SSc has long been an ongoing area of research. When damaged, 453 epithelial cells release signals that help induce fibroblast activation to promote wound healing⁸⁵. In SSc, 454 epidermal keratinocyte characteristics resemble a pro-fibrotic, activated state⁸⁶. SSc epidermal cells were also found to stimulate fibroblasts in culture⁸⁷, and some signs related to epithelial-mesenchymal transition 455 456 (EMT) have been observed in the SSc epidermis⁸⁸. The FLI1 (friend leukemia integration 1) transcription 457 factor, in particular, has received much attention for its potential role in epithelial-cell-mediated SSc pathogenesis²⁰. Lower FLI1 expression was observed in the epidermis of diffuse cutaneous SSc, and 458 459 inactivation of FLI1 in human keratinocytes in vitro induced gene expression changes characteristic of 460 SSc²⁴. Furthermore, conditional deletion of *Fli1* in epithelial cells produced an SSc-like phenotype in 461 mice²⁴. Importantly, the epithelial-cell-specific *Fli1* knockout further recapitulated the esophageal 462 involvement of SSc, with increased collagen deposition in the lamina propria combined with atrophy of the circular muscle layer, and the esophageal changes were not mediated by T-cell autoimmunity²⁴. In contrast 463 464 to these previous studies in mice and epidermal keratinocytes, we did not observe FLII expression in EECs 465 in any condition. FLII was expressed at low levels in endothelial cells, but the expression differences 466 between SSc, HCs, and GERD were not significant. We did observe significantly increased expression in 467 SSc and GERD of the P13 gene, which encodes trappin-2/elafin, previously found to be induced by Fli1 468 silencing in human dermal microvascular endothelial cells⁸⁹. However, this association is unlikely to be 469 pathogenic, as the increase in gene expression was greater in GERD, and a growing body of evidence 470 indicates that trappin-2/elafin is expressed to promote tissue repair in response to gastrointestinal tissue 471 inflammation⁹⁰.

While there have been many studies of epithelial cells in skin in SSc, molecular study of the human esophagus in SSc had heretofore been limited to one array-based gene expression study in bulk tissue conducted by Taroni and colleagues¹⁵, in which they identified distinct expression signatures among variable genes between 15 individuals with SSc that were similar to those seen in skin⁹¹. These signatures were independent of clinically defined SSc subsets¹⁵, suggestive of inter-individual heterogeneity in SSc.

They also found that gene expression patterns between upper and lower esophageal biopsies within individuals were nearly identical. They did not observe statistical associations between inflammatory gene expression signatures and GERD, but the study was underpowered for such an analysis, and GERD was defined based on histological evidence for basal cell hyperplasia and intraepithelial lymphocyte counts.

481 The gene expression differences we observed in SSc epithelial cells were highly correlated with 482 those seen in GERD, and nearly all differential gene expression was limited to the superficial layers of the 483 epithelium. These observations suggest that the primary driver of differential gene expression in EECs in 484 SSc is chronic acid exposure. The genes with the strongest mutual upregulation in SSc and GERD were 485 primarily related to keratinization/cornification, including small proline-rich proteins (SPRRs), serine 486 protease inhibitors (serpins), S100 proteins, late cornified envelope (LCE) genes, and keratins associated 487 with terminal epithelial differentiation, namely KRTDAP and KRT. KRTI helps maintain epithelial barrier 488 function in gastrointestinal epithelial cells, and its overexpression was shown to attenuate IL-1β-induced 489 epithelial permeability⁹². The mutual upregulation of these genes in the outer layers of the epithelium 490 therefore likely represent a protective response to chronic acid exposure.

491 While the overall gene expression differences were highly correlated between SSc and GERD, 492 there were sets of genes disproportionately upregulated in SSc that hint at disease-related immune response 493 aberrations, including genes that have previously been implicated in SSc pathogenesis. For example, 494 PTGES, which encodes prostaglandin E synthase, was previously found to be significantly upregulated in SSc fibroblasts⁹³ and inflammatory non-classical monocytes⁹⁴, and Ptges-null mice were resistant to 495 496 bleomycin-induced fibrosis⁹³. CD44 and CD74 form the receptor complex for the macrophage inhibitory 497 factor (MIF), an inflammatory cytokine that promotes fibroblast migration and has been implicated in SSc 498 pathogenesis⁹⁵. LTB4R (Leukotriene B4 Receptor, or BLT1) has been found to activate AKT/mTOR 499 signaling and knockdown of LTB4R attenuated fibrosis in bleomycin-induced SSc in murine models⁹⁶. 500 Serum HBEGF (heparin-binding epidermal growth factor) levels and fibroblast HBEGF expression were both significantly elevated in SSc⁹⁷. Copy number variation of APOBEC3A was significantly associated 501 502 with SSc in a Han Chinese population⁹⁸. Finally, the SSc-specific upregulation of genes involved in antigen

processing and presentation (*HLA-B*, *CD74*, *TAP1*, *PSMB8*, *PSMB9*) are suggestive of increased human leukocyte antigen (HLA) class I activity in superficial EECs in SSc. Notably, *TAP1*, *PSMB8*, and *PSMB9* are located immediately adjacent to one another in the class II region of the HLA locus, which is the genomic region with the strongest genetic associations with SSc⁹⁹, and SSc-associated HLA-B alleles have also been identified^{100,101}.

508 The most striking set of genes that were uniquely downregulated in SSc were metallothioneins. 509 The expression of detected metallothioneins (MT1A, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, MT2A) 510 was strongly induced in the superficial compartment of EECs, but significantly less so in SSc and, 511 interestingly, only in the proximal esophagus. We further observed a nominal association between relative 512 metallothionein expression in the proximal esophagus and the first PC of esophageal dysmotility among 513 SSc patients, with lower expression of metallothioneins correlated with greater EGJ distensibility and 514 weaker contractility. The proportion of the primary metallothionein-expressing cluster within superficial 515 EECs was likewise significantly associated with clinical PC1. The metallothioneins are a family of well-516 conserved, metal-binding proteins that regulate zinc and copper homeostasis, prevent heavy metal 517 poisoning, and combat oxidative stress^{102,103}. Their study in a wide array of physiological conditions and 518 immune-mediated diseases has revealed the proteins play central roles in innate and adaptive immunity, 519 including autoimmunity, but their immunoregulatory behavior is highly complex and context-specific^{102,103}. 520 Given their import in immune regulation, their associations with SSc and esophageal motility reported in 521 this study, and the connection between SSc and heavy metal exposure¹⁰⁴, the metallothioneins are 522 compelling candidates that warrant further study in SSc.

Interestingly, there was greater relative gene dysregulation in the proximal esophagus compared to the distal esophagus in SSc, but the opposite was true for GERD. This discrepancy suggests that esophageal dysmotility in SSc leads to greater acid exposure in the proximal esophagus, since refluxed gastric acid typically affects the distal esophagus significantly more than the proximal esophagus¹⁰⁵ and abnormal peristalsis prolongs acid clearance¹⁰⁶. This finding coincides with a bulk RNA-seq study of esophageal mucosa of achalasia patients¹⁰⁷, which likewise identified more differential expression in the proximal

esophagus than in the distal esophagus, including significant enrichment of matrisome-associated genes and lower expression of genes associated with reactive oxygen species metabolism¹⁰⁷. Due to differences in innervation depth¹⁰⁸, the epithelium of the proximal esophagus has more nociceptive sensitivity than the distal esophagus, which likely contributes to the association between gastrointestinal symptoms and lower quality of life in SSc¹⁰⁹. Proximal acid exposure increases the risk of aspiration¹¹⁰ and is significantly more prevalent in SSc patients with idiopathic lung fibrosis¹¹¹.

535 Targets for several transcription factors, including IRF1, MYC, E2F4, and NFE2L2 (or NRF2), 536 were significantly enriched among DEGs in superficial EECs from the proximal esophagus. IRF1 is 537 involved innate immune responses, but while IRF1 targets were enriched in DEGs between SSc and GERD, 538 the enrichment appeared to be driven by upregulation in GERD. IRF1 targets were not enriched in DEGs 539 between SSc and HCs, nor was IRF1 significantly differentially expressed in SSc. MYC, E2F4, and NFE2L2 all participate in different stages of the cell cycle¹¹²⁻¹¹⁴, and expression of each was highest in 540 541 either the proliferating basal or suprabasal compartments, but these proteins may also play a role in terminal 542 differentiation of EECs, particularly under conditions of stress. In the least differentiated superficial cluster 543 (cluster 5), where the expression differences relative to HCs for each of these transcription factors and their 544 targets was most pronounced, the expression level changes in GERD were correlated with those observed 545 in SSc. Furthermore, Myc ablation in Krt14-expressing tissues in mice led to abnormal terminal 546 differentiation of epithelial cells¹¹⁵, and a study of the esophageal epithelium in Nrf2 knockout mice 547 indicated that Nrf2 regulates cornification of keratinized epithelial cells under conditions of stress¹¹⁶.

There are important limitations to consider when interpreting this study. First, this study only focused on squamous epithelial cells. There may be relevant changes in other cell types within the esophageal mucosa that correlate with SSc and dysmotility, but such analyses are ongoing and were outside the scope of this investigation. Second, the relatively small patient sample size of this study combined with the heterogeneity of SSc subtypes and dysmotility phenotypes limited our power to detect clinical associations between cell type proportions or gene expression changes and specific clinical phenotypes. Heterogeneous molecular profiles in SSc esophagus samples have been described previously¹⁵, but we

555 grouped all SSc patients together in our analyses for comparisons against GERD and HCs. We applied 556 ordinal logistic regression on motility classifications and performed principal components analysis on 557 reflux- and motility-related quantitative traits to increase our power to detect clinical associations but were 558 nonetheless statistically limited by sample size. Third, we did not examine imaging data in the SSc 559 esophageal mucosa. Therefore, we cannot make conclusions on the morphological states that accompany 560 the transcriptional and cellular proportion changes that we observed. Future studies utilizing larger, more 561 homogeneous cohorts with imaging data may be able to detect more esophageal epithelial changes 562 associated with dysmotility in SSc.

563 In summary, esophageal complications are common in individuals with SSc and can greatly impact 564 quality of life and lifespan. In this study, we sought to clarify the role of the epithelium in SSc esophageal 565 involvement. Through a thorough, single-cell-level transcriptomic investigation, we identified the unique 566 cellular and transcriptional differences present in the SSc esophageal epithelium. There were significantly 567 fewer terminally differentiated epithelial cells in the outermost, superficial layers in both the proximal and 568 distal esophagus, but otherwise epithelial compartment proportions were similar to healthy controls, 569 including proliferating cell proportions. Significant differences in gene expression were likewise almost 570 exclusively found in the superficial compartment, and these changes were highly correlated with those seen 571 in individuals with GERD, indicating that the primary driver of differential gene expression in the SSc 572 esophageal epithelium is chronic acid exposure. Transcriptional differences were also more prominent in 573 the proximal esophagus of SSc patients, suggesting that esophageal dysmotility leads to greater proximal 574 exposure. Genes that were most disproportionately dysregulated in SSc compared to GERD belonged to 575 immune-related pathways, including innate and adaptive response, antigen presentation, and metal 576 homeostasis, and may therefore point to pathogenic immune dysfunction. Future studies investigating these 577 pathways in non-epithelial cell populations in more homogeneous SSc cohorts may further resolve the 578 pathogenic mechanisms driving esophageal involvement in SSc. By serving as an atlas for the human 579 esophageal epithelium in SSc, this study can guide future efforts to address remaining gaps in our

- 580 understanding of the SSc esophagus, to ultimately uncover pathogenic mechanisms and identify actionable
- 581 targets.

582 **REFERENCES**

- Bairkdar, M., Rossides, M., Westerlind, H., Hesselstrand, R., Arkema, E.V., and Holmqvist, M.
 (2021). Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford) *60*, 3121-3133. 10.1093/rheumatology/keab190.
- Fan, Y., Bender, S., Shi, W., and Zoz, D. (2020). Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States. J Manag Care Spec Pharm 26, 1539-1547. 10.18553/jmcp.2020.20136.
- Tian, J., Kang, S., Zhang, D., Huang, Y., Zhao, M., Gui, X., Yao, X., and Lu, Q. (2023). Global,
 regional, and national incidence and prevalence of systemic sclerosis. Clin Immunol 248, 109267.
 10.1016/j.clim.2023.109267.
- Pope, J.E., Quansah, K., Hassan, S., Seung, S.J., Flavin, J., and Kolb, M. (2021). Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. J Rheumatol 48, 1427-1434. 10.3899/jrheum.201049.
- 595 5. Li, J.X. (2022). Secular Trends in Systemic Sclerosis Mortality in the United States from 1981 to 596 2020. Int J Environ Res Public Health *19*. 10.3390/ijerph192215088.
- 6. Rubio-Rivas, M., Royo, C., Simeon, C.P., Corbella, X., and Fonollosa, V. (2014). Mortality and
 survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum 44, 208219. 10.1016/j.semarthrit.2014.05.010.
- Bairkdar, M., Chen, E.Y., Dickman, P.W., Hesselstrand, R., Westerlind, H., and Holmqvist, M.
 (2023). Survival in Swedish patients with systemic sclerosis: a nationwide population-based matched
 cohort study. Rheumatology (Oxford) *62*, 1170-1178. 10.1093/rheumatology/keac474.
- 8. Li, B., Yan, J., Pu, J., Tang, J., Xu, S., and Wang, X. (2021). Esophageal Dysfunction in Systemic
 Sclerosis: An Update. Rheumatol Ther *8*, 1535-1549. 10.1007/s40744-021-00382-0.
- 605
 9. Emmanuel, A. (2016). Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol *13*, 461-472. 10.1038/nrgastro.2016.99.
- 607 10. Ahuja, N.K., and Clarke, J.O. (2021). Scleroderma and the Esophagus. Gastroenterol Clin North Am
 608 50, 905-918. 10.1016/j.gtc.2021.08.005.
- 11. Denaxas, K., Ladas, S.D., and Karamanolis, G.P. (2018). Evaluation and management of esophageal
 manifestations in systemic sclerosis. Ann Gastroenterol *31*, 165-170. 10.20524/aog.2018.0228.
- 611
 12. Foocharoen, C., Thinkhamrop, W., Chaichaya, N., Mahakkanukrauh, A., Suwannaroj, S., and
 612 Thinkhamrop, B. (2022). Development and validation of machine learning for early mortality in
 613 systemic sclerosis. Sci Rep *12*, 17178. 10.1038/s41598-022-22161-9.
- 614 13. Sjogren, R.W. (1994). Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 37, 1265615 1282. 10.1002/art.1780370902.
- 616 14. Roberts, C.G., Hummers, L.K., Ravich, W.J., Wigley, F.M., and Hutchins, G.M. (2006). A case617 control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 55,
 618 1697-1703. 10.1136/gut.2005.086074.
- 15. Taroni, J.N., Martyanov, V., Huang, C.C., Mahoney, J.M., Hirano, I., Shetuni, B., Yang, G.Y.,
 Brenner, D., Jung, B., Wood, T.A., et al. (2015). Molecular characterization of systemic sclerosis
 esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Res Ther 17, 194.
 10.1186/s13075-015-0695-1.
- Roman, S., Hot, A., Fabien, N., Cordier, J.F., Miossec, P., Ninet, J., Mion, F., and Reseau
 Sclerodermie des Hospices Civils de, L. (2011). Esophageal dysmotility associated with systemic
 sclerosis: a high-resolution manometry study. Dis Esophagus 24, 299-304. 10.1111/j.14422050.2010.01150.x.
- 17. Noviani, M., Chellamuthu, V.R., Albani, S., and Low, A.H.L. (2022). Toward Molecular
 Stratification and Precision Medicine in Systemic Sclerosis. Front Med (Lausanne) 9, 911977.
 10.3389/fmed.2022.911977.
- 630 18. Carlson, D.A., Crowell, M.D., Kimmel, J.N., Patel, A., Gyawali, C.P., Hinchcliff, M., Griffing, W.L.,
 631 Pandolfino, J.E., and Vela, M.F. (2016). Loss of Peristaltic Reserve, Determined by Multiple Rapid

- Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic
 Sclerosis. Clin Gastroenterol Hepatol 14, 1502-1506. 10.1016/j.cgh.2016.03.039.
- Kimmel, J.N., Carlson, D.A., Hinchcliff, M., Carns, M.A., Aren, K.A., Lee, J., and Pandolfino, J.E.
 (2016). The association between systemic sclerosis disease manifestations and esophageal highresolution manometry parameters. Neurogastroenterol Motil 28, 1157-1165. 10.1111/nmo.12813.
- 637 20. Asano, Y., Takahashi, T., and Saigusa, R. (2019). Systemic sclerosis: Is the epithelium a missing
 638 piece of the pathogenic puzzle? J Dermatol Sci 94, 259-265. 10.1016/j.jdermsci.2019.04.007.
- burcan, C., Hossain, M., Chagnon, G., Peric, D., Karam, G., Bsiesy, L., and Girard, E. (2022).
 Experimental investigations of the human oesophagus: anisotropic properties of the embalmed
 mucosa-submucosa layer under large deformation. Biomech Model Mechanobiol 21, 1685-1702.
 10.1007/s10237-022-01613-1.
- Kou, W., Pandolfino, J.E., Kahrilas, P.J., and Patankar, N.A. (2017). Simulation studies of the role of
 esophageal mucosa in bolus transport. Biomech Model Mechanobiol *16*, 1001-1009. 10.1007/s10237016-0867-1.
- 646
 647
 23. Asano, Y., Bujor, A.M., and Trojanowska, M. (2010). The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis. J Dermatol Sci 59, 153-162. 10.1016/j.jdermsci.2010.06.008.
- 24. Takahashi, T., Asano, Y., Sugawara, K., Yamashita, T., Nakamura, K., Saigusa, R., Ichimura, Y.,
 Toyama, T., Taniguchi, T., Akamata, K., et al. (2017). Epithelial Fli1 deficiency drives systemic
 autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med 214, 1129-1151.
 10.1084/jem.20160247.
- binh, H.Q., Pan, F., Wang, G., Huang, Q.F., Olingy, C.E., Wu, Z.Y., Wang, S.H., Xu, X., Xu, X.E.,
 He, J.Z., et al. (2021). Integrated single-cell transcriptome analysis reveals heterogeneity of
 esophageal squamous cell carcinoma microenvironment. Nat Commun *12*, 7335. 10.1038/s41467021-27599-5.
- 26. Zhang, X., Peng, L., Luo, Y., Zhang, S., Pu, Y., Chen, Y., Guo, W., Yao, J., Shao, M., Fan, W., et al.
 (2021). Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic
 analysis. Nat Commun *12*, 5291. 10.1038/s41467-021-25539-x.
- 27. Rochman, M., Wen, T., Kotliar, M., Dexheimer, P.J., Ben-Baruch Morgenstern, N., Caldwell, J.M.,
 Lim, H.W., and Rothenberg, M.E. (2022). Single-cell RNA-Seq of human esophageal epithelium in
 homeostasis and allergic inflammation. JCI Insight 7. 10.1172/jci.insight.159093.
- 28. Clevenger, M.H., Karami, A.L., Carlson, D.A., Kahrilas, P.J., Gonsalves, N., Pandolfino, J.E.,
 Winter, D.R., Whelan, K.A., and Tetreault, M.P. (2023). Suprabasal cells retain progenitor cell
 identity programs in eosinophilic esophagitis-driven basal cell hyperplasia. JCI Insight 8.
 10.1172/jci.insight.171765.
- 29. Carlson, D.A., Prescott, J.E., Germond, E., Brenner, D., Carns, M., Correia, C.S., Tetreault, M.P.,
 McMahan, Z.H., Hinchcliff, M., Kou, W., et al. (2022). Heterogeneity of primary and secondary
 peristalsis in systemic sclerosis: A new model of "scleroderma esophagus". Neurogastroenterol Motil
 34, e14284. 10.1111/nmo.14284.
- 30. Carlson, D.A., Gyawali, C.P., Khan, A., Yadlapati, R., Chen, J., Chokshi, R.V., Clarke, J.O., Garza,
 J.M., Jain, A.S., Katz, P., et al. (2021). Classifying Esophageal Motility by FLIP Panometry: A Study
 of 722 Subjects With Manometry. Am J Gastroenterol *116*, 2357-2366.
 10.14309/ajg.00000000001532.
- Koop, A.H., Kahrilas, P.J., Schauer, J., Pandolfino, J.E., and Carlson, D.A. (2023). The impact of
 primary peristalsis, contractile reserve, and secondary peristalsis on esophageal clearance measured
 by timed barium esophagogram. Neurogastroenterol Motil, e14638. 10.1111/nmo.14638.
- 32. Yadlapati, R., Kahrilas, P.J., Fox, M.R., Bredenoord, A.J., Prakash Gyawali, C., Roman, S., Babaei,
 A., Mittal, R.K., Rommel, N., Savarino, E., et al. (2021). Esophageal motility disorders on highresolution manometry: Chicago classification version 4.0((c)). Neurogastroenterol Motil *33*, e14058.
 10.1111/nmo.14058.
- Stern, E.K., Carlson, D.A., Falmagne, S., Hoffmann, A.D., Carns, M., Pandolfino, J.E., Hinchcliff,
 M., and Brenner, D.M. (2018). Abnormal esophageal acid exposure on high-dose proton pump

683 inhibitor therapy is common in systemic sclerosis patients. Neurogastroenterol Motil *30*.
684 10.1111/nmo.13247.

- 34. Yadlapati, R., Kahrilas, P.J., Fox, M.R., Bredenoord, A.J., Prakash Gyawali, C., Roman, S., Babaei,
 A., Mittal, R.K., Rommel, N., Savarino, E., et al. (2021). Esophageal motility disorders on highresolution manometry: Chicago classification version 4.0(©). Neurogastroenterol Motil *33*, e14058.
 10.1111/nmo.14058.
- Soney, K.P., Baumann, A.J., Donnan, E., Kou, W., Triggs, J.R., Prescott, J., Decorrevont, A.,
 Dorian, E., Kahrilas, P.J., Pandolfino, J.E., and Carlson, D.A. (2021). Esophagogastric Junction
 Opening Parameters Are Consistently Abnormal in Untreated Achalasia. Clin Gastroenterol Hepatol
 19, 1058-1060.e1051. 10.1016/j.cgh.2020.03.069.
- 693 36. Carlson, D.A., Baumann, A.J., Donnan, E.N., Krause, A., Kou, W., and Pandolfino, J.E. (2021).
 694 Evaluating esophageal motility beyond primary peristalsis: Assessing esophagogastric junction
 695 opening mechanics and secondary peristalsis in patients with normal manometry. Neurogastroenterol
 696 Motil *33*, e14116. 10.1111/nmo.14116.
- 697 37. Carlson, D.A., Kou, W., Lin, Z., Hinchcliff, M., Thakrar, A., Falmagne, S., Prescott, J., Dorian, E.,
 698 Kahrilas, P.J., and Pandolfino, J.E. (2019). Normal Values of Esophageal Distensibility and
 699 Distension-Induced Contractility Measured by Functional Luminal Imaging Probe Panometry. Clin
 700 Gastroenterol Hepatol *17*, 674-681 e671. 10.1016/j.cgh.2018.07.042.
- 38. Jonasson, C., Wernersson, B., Hoff, D.A., and Hatlebakk, J.G. (2013). Validation of the GerdQ
 questionnaire for the diagnosis of gastro-oesophageal reflux disease. Aliment Pharmacol Ther *37*,
 564-572. 10.1111/apt.12204.
- 39. Taft, T.H., Riehl, M., Sodikoff, J.B., Kahrilas, P.J., Keefer, L., Doerfler, B., and Pandolfino, J.E.
 (2016). Development and validation of the brief esophageal dysphagia questionnaire.
 Neurogastroenterol Motil 28, 1854-1860. 10.1111/nmo.12889.
- 40. Bedell, A., Taft, T.H., Keefer, L., and Pandolfino, J. (2016). Development of the Northwestern
 Esophageal Quality of Life Scale: A Hybrid Measure for Use Across Esophageal Conditions. Am J
 Gastroenterol 111, 493-499. 10.1038/ajg.2016.20.
- 41. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., 3rd, Zheng, S., Butler, A., Lee, M.J., Wilk,
 A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. Cell 184,
 3573-3587 e3529. 10.1016/j.cell.2021.04.048.
- 42. Hippen, A.A., Falco, M.M., Weber, L.M., Erkan, E.P., Zhang, K., Doherty, J.A., Vaharautio, A.,
 Greene, C.S., and Hicks, S.C. (2021). miQC: An adaptive probabilistic framework for quality control
 of single-cell RNA-sequencing data. PLoS Comput Biol *17*, e1009290.
 10.1371/journal.pcbi.1009290.
- 43. Germain, P.L., Lun, A., Garcia Meixide, C., Macnair, W., and Robinson, M.D. (2021). Doublet
 identification in single-cell sequencing data using scDblFinder. F1000Res 10, 979.
 10.12688/f1000research.73600.2.
- 44. Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell RNAseq data using regularized negative binomial regression. Genome Biol 20, 296. 10.1186/s13059-0191874-1.
- 45. Lause, J., Berens, P., and Kobak, D. (2021). Analytic Pearson residuals for normalization of singlecell RNA-seq UMI data. Genome Biol 22, 258. 10.1186/s13059-021-02451-7.
- 46. McInnes, L., Healy, J., and Melville, J. (2018). UMAP: Uniform Manifold Approximation and
 Projection for Dimension Reduction. arXiv:1802.03426. 10.48550/arXiv.1802.03426.
- 47. Clevenger, M.H., Karami, A.L., Carlson, D.A., Kahrilas, P.J., Gonsalves, N., Pandolfino, J.E.,
 Winter, D.R., Whelan, K.A., and Tetreault, M.P. (2023). Suprabasal cells retaining stem cell identity
 programs drive basal cell hyperplasia in eosinophilic esophagitis. bioRxiv.
 10.1101/2023.04.20.537495.
- 48. Busslinger, G.A., Weusten, B.L.A., Bogte, A., Begthel, H., Brosens, L.A.A., and Clevers, H. (2021).
 Human gastrointestinal epithelia of the esophagus, stomach, and duodenum resolved at single-cell
 resolution. Cell Rep *34*, 108819. 10.1016/j.celrep.2021.108819.

- 49. Kabir, M.F., Karami, A.L., Cruz-Acuna, R., Klochkova, A., Saxena, R., Mu, A., Murray, M.G., Cruz,
 J., Fuller, A.D., Clevenger, M.H., et al. (2022). Single cell transcriptomic analysis reveals cellular
 diversity of murine esophageal epithelium. Nat Commun *13*, 2167. 10.1038/s41467-022-29747-x.
- 50. Okumura, T., Shimada, Y., Imamura, M., and Yasumoto, S. (2003). Neurotrophin receptor p75(NTR)
 characterizes human esophageal keratinocyte stem cells in vitro. Oncogene 22, 4017-4026.
 10.1038/sj.onc.1206525.
- 51. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H., 2nd, Treacy, D., Trombetta, J.J., Rotem, A.,
 Rodman, C., Lian, C., Murphy, G., et al. (2016). Dissecting the multicellular ecosystem of metastatic
 melanoma by single-cell RNA-seq. Science *352*, 189-196. 10.1126/science.aad0501.
- 52. Fonseka, C.Y., Rao, D.A., Teslovich, N.C., Korsunsky, I., Hannes, S.K., Slowikowski, K., Gurish,
 M.F., Donlin, L.T., Lederer, J.A., Weinblatt, M.E., et al. (2018). Mixed-effects association of single
 cells identifies an expanded effector CD4(+) T cell subset in rheumatoid arthritis. Sci Transl Med *10*.
 10.1126/scitranslmed.aaq0305.
- 53. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P.,
 Carlsson, E., Ridderstrale, M., Laurila, E., et al. (2003). PGC-1alpha-responsive genes involved in
 oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet *34*, 267-273.
 10.1038/ng1180.
- 54. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich,
 A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis:
 a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U
 S A *102*, 15545-15550. 10.1073/pnas.0506580102.
- 55. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P. (2015). The
 Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst 1, 417-425.
 10.1016/j.cels.2015.12.004.
- 56. Squair, J.W., Gautier, M., Kathe, C., Anderson, M.A., James, N.D., Hutson, T.H., Hudelle, R.,
 Qaiser, T., Matson, K.J.E., Barraud, Q., et al. (2021). Confronting false discoveries in single-cell
 differential expression. Nat Commun *12*, 5692. 10.1038/s41467-021-25960-2.
- 57. Chen, Y., Lun, A.T., and Smyth, G.K. (2016). From reads to genes to pathways: differential
 expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood
 pipeline. F1000Res 5, 1438. 10.12688/f1000research.8987.2.
- 58. McCarthy, D.J., Chen, Y., and Smyth, G.K. (2012). Differential expression analysis of multifactor
 RNA-Seq experiments with respect to biological variation. Nucleic Acids Res 40, 4288-4297.
 10.1093/nar/gks042.
- 767 59. Robinson, M.D., McCarthy, D.J., and Smyth, G.K. (2010). edgeR: a Bioconductor package for
 768 differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140.
 769 10.1093/bioinformatics/btp616.
- 60. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan, L., et al.
 (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation
 (Camb) 2, 100141. 10.1016/j.xinn.2021.100141.
- 61. Consortium, E.P. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature
 489, 57-74. 10.1038/nature11247.
- 62. Lachmann, A., Xu, H., Krishnan, J., Berger, S.I., Mazloom, A.R., and Ma'ayan, A. (2010). ChEA:
 transcription factor regulation inferred from integrating genome-wide ChIP-X experiments.
 Bioinformatics 26, 2438-2444. 10.1093/bioinformatics/btq466.
- Kou, Y., Chen, E.Y., Clark, N.R., Duan, Q., Tan, C.M., and Ma'ayan, A. (2013). ChEA2: Gene-Set
 Libraries from ChIP-X Experiments to Decode the Transcription Regulome. held in Berlin,
 Heidelberg, (Springer Berlin Heidelberg), pp. 416-430.
- 64. Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma'ayan, A.
 (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC
 Bioinformatics 14, 128. 10.1186/1471-2105-14-128.

- 65. Hou, W., Ji, Z., Chen, Z., Wherry, E.J., Hicks, S.C., and Ji, H. (2023). A statistical framework for
 differential pseudotime analysis with multiple single-cell RNA-seq samples. Nat Commun 14, 7286.
 10.1038/s41467-023-42841-y.
- 66. Wang, Q., Li, Y., Wu, M., Huang, S., Zhang, A., Zhang, Y., and Jia, Z. (2021). Targeting microsomal prostaglandin E synthase 1 to develop drugs treating the inflammatory diseases. Am J Transl Res 13, 391-419.
- 67. Yi, Y.S. (2016). Functional Role of Milk Fat Globule-Epidermal Growth Factor VIII in Macrophage Mediated Inflammatory Responses and Inflammatory/Autoimmune Diseases. Mediators Inflamm
 2016, 5628486. 10.1155/2016/5628486.
- 68. Oh, S., Bournique, E., Bowen, D., Jalili, P., Sanchez, A., Ward, I., Dananberg, A., Manjunath, L.,
 Tran, G.P., Semler, B.L., et al. (2021). Genotoxic stress and viral infection induce transient
 expression of APOBEC3A and pro-inflammatory genes through two distinct pathways. Nat Commun *12*, 4917. 10.1038/s41467-021-25203-4.
- 797 69. Tiwari, R., de la Torre, J.C., McGavern, D.B., and Nayak, D. (2019). Beyond Tethering the Viral
 798 Particles: Immunomodulatory Functions of Tetherin (BST-2). DNA Cell Biol *38*, 1170-1177.
 799 10.1089/dna.2019.4777.
- 70. Baaten, B.J., Li, C.R., and Bradley, L.M. (2010). Multifaceted regulation of T cells by CD44.
 Commun Integr Biol *3*, 508-512. 10.4161/cib.3.6.13495.
- Kole and Solar Strain Strain
- 72. Okamoto, Y., and Shikano, S. (2023). Emerging roles of a chemoattractant receptor GPR15 and
 ligands in pathophysiology. Front Immunol *14*, 1179456. 10.3389/fimmu.2023.1179456.
- 807 73. Subramanian, B.C., Moissoglu, K., and Parent, C.A. (2018). The LTB(4)-BLT1 axis regulates the
 808 polarized trafficking of chemoattractant GPCRs during neutrophil chemotaxis. J Cell Sci *131*.
 809 10.1242/jcs.217422.
- 74. Nguyen, H.T., Reyes-Alcaraz, A., Yong, H.J., Nguyen, L.P., Park, H.K., Inoue, A., Lee, C.S., Seong,
 J.Y., and Hwang, J.I. (2020). CXCR7: a beta-arrestin-biased receptor that potentiates cell migration
 and recruits beta-arrestin2 exclusively through Gbetagamma subunits and GRK2. Cell Biosci 10, 134.
 10.1186/s13578-020-00497-x.
- 814 75. Kelly, A., and Trowsdale, J. (2019). Genetics of antigen processing and presentation.
 815 Immunogenetics *71*, 161-170. 10.1007/s00251-018-1082-2.
- 816
 76. Bartel, Y., Bauer, B., and Steinle, A. (2013). Modulation of NK cell function by genetically coupled
 817
 C-type lectin-like receptor/ligand pairs encoded in the human natural killer gene complex. Front
 818
 Immunol 4, 362. 10.3389/fimmu.2013.00362.
- 77. Lu, R.Q., Zhang, Y.Y., Zhao, H.Q., Guo, R.Q., Jiang, Z.X., and Guo, R. (2022). SGK1, a Critical
 Regulator of Immune Modulation and Fibrosis and a Potential Therapeutic Target in Chronic GraftVersus-Host Disease. Front Immunol *13*, 822303. 10.3389/fimmu.2022.822303.
- 78. Li, Y., Su, G., Zhong, Y., Xiong, Z., Huang, T., Quan, J., Huang, J., Wen, X., Luo, C., Zheng, W., et
 al. (2021). HB-EGF-induced IL-8 secretion from airway epithelium leads to lung fibroblast
 proliferation and migration. BMC Pulm Med *21*, 347. 10.1186/s12890-021-01726-w.
- 79. Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson,
 A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015). Proteomics. Tissue-based map of the human
 proteome. Science *347*, 1260419. 10.1126/science.1260419.
- 80. Politi, E., Angelakopoulou, A., Grapsa, D., Zande, M., Stefanaki, K., Panagiotou, I., Roma, E., and
 Syrigou, E. (2017). Filaggrin and Periostin Expression Is Altered in Eosinophilic Esophagitis and
 Normalized With Treatment. J Pediatr Gastroenterol Nutr 65, 47-52.
 10.1097/MPG.00000000001419.
- 81. Oshima, N., Ishihara, S., Fukuba, N., Mishima, Y., Kawashima, K., Ishimura, N., Ishikawa, N.,
 Maruyama, R., and Kinoshita, Y. (2017). Epidermal differentiation complex protein involucrin is
 down-regulated in eosinophilic esophagitis. Esophagus 14, 171-177. 10.1007/s10388-016-0568-y.

- 82. Yu, T., Yang, X., Fu, Q., Liang, J., Wu, X., Sheng, J., Chen, Y., Xiao, L., Wu, Y., Nie, D., et al.
 (2023). TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of
 AIM2. Cell Rep 42, 113231. 10.1016/j.celrep.2023.113231.
- AIM2. Cell Rep 42, 113231. 10.1016/j.celrep.2023.113231.
 838
 83. Crowell, M.D., Umar, S.B., Griffing, W.L., DiBaise, J.K., Lacy, B.E., and Vela, M.F. (2017).
 839 Esophageal Motor Abnormalities in Patients With Scleroderma: Heterogeneity, Risk Factors, and
 840 Effects on Quality of Life. Clin Gastroenterol Hepatol 15, 207-213 e201. 10.1016/j.cgh.2016.08.034.
- 84. Forbes, A., and Marie, I. (2009). Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford) *48 Suppl 3*, iii36-39.
 843 10.1093/rheumatology/ken485.
- 844 85. Krieg, T., Abraham, D., and Lafyatis, R. (2007). Fibrosis in connective tissue disease: the role of the
 myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther *9 Suppl 2*, S4.
 10.1186/ar2188.
- 86. Aden, N., Shiwen, X., Aden, D., Black, C., Nuttall, A., Denton, C.P., Leask, A., Abraham, D., and
 Stratton, R. (2008). Proteomic analysis of scleroderma lesional skin reveals activated wound healing
 phenotype of epidermal cell layer. Rheumatology (Oxford) 47, 1754-1760.
 10.1093/rheumatology/ken370.
- 87. Aden, N., Nuttall, A., Shiwen, X., de Winter, P., Leask, A., Black, C.M., Denton, C.P., Abraham,
 D.J., and Stratton, R.J. (2010). Epithelial cells promote fibroblast activation via IL-1alpha in systemic
 sclerosis. J Invest Dermatol *130*, 2191-2200. 10.1038/jid.2010.120.
- 854 88. Nikitorowicz-Buniak, J., Denton, C.P., Abraham, D., and Stratton, R. (2015). Partially Evoked
 855 Epithelial-Mesenchymal Transition (EMT) Is Associated with Increased TGFbeta Signaling within
 856 Lesional Scleroderma Skin. PLoS One *10*, e0134092. 10.1371/journal.pone.0134092.
- 89. Miyagawa, T., Asano, Y., Saigusa, R., Hirabayashi, M., Yamashita, T., Taniguchi, T., Takahashi, T.,
 Nakamura, K., Miura, S., Yoshizaki, A., et al. (2019). A potential contribution of trappin-2 to the
 development of vasculopathy in systemic sclerosis. J Eur Acad Dermatol Venereol *33*, 753-760.
 10.1111/jdv.15387.
- 90. Deraison, C., Bonnart, C., Langella, P., Roget, K., and Vergnolle, N. (2023). Elafin and its precursor
 trappin-2: What is their therapeutic potential for intestinal diseases? Br J Pharmacol 180, 144-160.
 10.1111/bph.15985.
- 864 91. Hinchcliff, M., Huang, C.C., Wood, T.A., Matthew Mahoney, J., Martyanov, V., Bhattacharyya, S.,
 865 Tamaki, Z., Lee, J., Carns, M., Podlusky, S., et al. (2013). Molecular signatures in skin associated
 866 with clinical improvement during mycophenolate treatment in systemic sclerosis. J Invest Dermatol
 867 133, 1979-1989. 10.1038/jid.2013.130.
- 92. Dong, X., Liu, Z., Lan, D., Niu, J., Miao, J., Yang, G., Zhang, F., Sun, Y., Wang, K., and Miao, Y.
 (2017). Critical role of Keratin 1 in maintaining epithelial barrier and correlation of its downregulation with the progression of inflammatory bowel disease. Gene 608, 13-19.
 10.1016/j.gene.2017.01.015.
- 93. McCann, M.R., Monemdjou, R., Ghassemi-Kakroodi, P., Fahmi, H., Perez, G., Liu, S., Shi-Wen, X.,
 Parapuram, S.K., Kojima, F., Denton, C.P., et al. (2011). mPGES-1 null mice are resistant to
 bleomycin-induced skin fibrosis. Arthritis Res Ther 13, R6. 10.1186/ar3226.
- 94. Villanueva-Martin, G., Acosta-Herrera, M., Carmona, E.G., Kerick, M., Ortego-Centeno, N.,
 876 Callejas-Rubio, J.L., Mages, N., Klages, S., Borno, S., Timmermann, B., et al. (2023). Non-classical
 877 circulating monocytes expressing high levels of microsomal prostaglandin E2 synthase-1 tag an
 878 aberrant IFN-response in systemic sclerosis. J Autoimmun *140*, 103097. 10.1016/j.jaut.2023.103097.
- 95. Unlu, B., Tursen, U., Rajabi, Z., Jabalameli, N., and Rajabi, F. (2022). The Immunogenetics of
 Systemic Sclerosis. Adv Exp Med Biol *1367*, 259-298. 10.1007/978-3-030-92616-8 10.
- 881 96. Liang, M., Lv, J., Jiang, Z., He, H., Chen, C., Xiong, Y., Zhu, X., Xue, Y., Yu, Y., Yang, S., et al.
 (2020). Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B(4) Leukotriene B(4) Receptor Axis in Systemic Sclerosis. Arthritis Rheumatol 72, 1013-1025.
 10.1002/art.41192.

- 97. Hirabayashi, M., Asano, Y., Yamashita, T., Miura, S., Nakamura, K., Taniguchi, T., Saigusa, R.,
 886 Takahashi, T., Ichimura, Y., Miyagawa, T., et al. (2018). Possible pro-inflammatory role of heparinbinding epidermal growth factor-like growth factor in the active phase of systemic sclerosis. J
 B88 Dermatol 45, 182-188. 10.1111/1346-8138.14088.
- 98. Guo, S., Li, Y., Wang, Y., Chu, H., Chen, Y., Liu, Q., Guo, G., Tu, W., Wu, W., Zou, H., et al.
 (2016). Copy Number Variation of HLA-DQA1 and APOBEC3A/3B Contribute to the Susceptibility
 of Systemic Sclerosis in the Chinese Han Population. J Rheumatol 43, 880-886.
 10.3899/jrheum.150945.
- 893 99. Lopez-Isac, E., Acosta-Herrera, M., Kerick, M., Assassi, S., Satpathy, A.T., Granja, J., Mumbach,
 894 M.R., Beretta, L., Simeon, C.P., Carreira, P., et al. (2019). GWAS for systemic sclerosis identifies
 895 multiple risk loci and highlights fibrotic and vasculopathy pathways. Nat Commun *10*, 4955.
 896 10.1038/s41467-019-12760-y.
- 100. Acosta-Herrera, M., Kerick, M., Lopez-Isac, E., Assassi, S., Beretta, L., Simeon-Aznar, C.P.,
 Ortego-Centeno, N., International, S.G., Proudman, S.M., Australian Scleroderma Interest, G., et al.
 (2021). Comprehensive analysis of the major histocompatibility complex in systemic sclerosis
 identifies differential HLA associations by clinical and serological subtypes. Ann Rheum Dis *80*,
 1040-1047. 10.1136/annrheumdis-2021-219884.
- Hanson, A.L., Sahhar, J., Ngian, G.S., Roddy, J., Walker, J., Stevens, W., Nikpour, M., Assassi,
 S., Proudman, S., Mayes, M.D., et al. (2022). Contribution of HLA and KIR Alleles to Systemic
 Sclerosis Susceptibility and Immunological and Clinical Disease Subtypes. Front Genet *13*, 913196.
 10.3389/fgene.2022.913196.
- Dai, H., Wang, L., Li, L., Huang, Z., and Ye, L. (2021). Metallothionein 1: A New Spotlight on Inflammatory Diseases. Front Immunol 12, 739918. 10.3389/fimmu.2021.739918.
- 908
 909
 103. Subramanian Vignesh, K., and Deepe, G.S., Jr. (2017). Metallothioneins: Emerging Modulators
 909 in Immunity and Infection. Int J Mol Sci 18. 10.3390/ijms18102197.
- 910 104. Marie, I. (2019). Systemic sclerosis and exposure to heavy metals. Autoimmun Rev 18, 62-72.
 911 10.1016/j.autrev.2018.11.001.
- 912 105. Shaker, R., Dodds, W.J., Helm, J.F., Kern, M.K., and Hogan, W.J. (1991). Regional esophageal
 913 distribution and clearance of refluxed gastric acid. Gastroenterology 101, 355-359. 10.1016/0016914 5085(91)90011-9.
- 915 106. Diener, U., Patti, M.G., Molena, D., Fisichella, P.M., and Way, L.W. (2001). Esophageal
 916 dysmotility and gastroesophageal reflux disease. J Gastrointest Surg 5, 260-265. 10.1016/s1091917 255x(01)80046-9.
- 918 107. Patel, C.K., Kahrilas, P.J., Hodge, N.B., Tsikretsis, L.E., Carlson, D.A., Pandolfino, J.E., and
 919 Tetreault, M.P. (2022). RNA-sequencing reveals molecular and regional differences in the esophageal
 920 mucosa of achalasia patients. Sci Rep *12*, 20616. 10.1038/s41598-022-25103-7.
- Woodland, P., Aktar, R., Mthunzi, E., Lee, C., Peiris, M., Preston, S.L., Blackshaw, L.A., and
 Sifrim, D. (2015). Distinct afferent innervation patterns within the human proximal and distal
 esophageal mucosa. Am J Physiol Gastrointest Liver Physiol *308*, G525-531.
 10.1152/ajpgi.00175.2014.
- Sandqvist, G., and Hesselstrand, R. (2019). Validity of the Swedish version of the systemic
 sclerosis quality of life questionnaire (SSCQoL): A novel measure of quality of life for patients with
 systemic sclerosis. Ann Rheum Dis 78, 855-857. 10.1136/annrheumdis-2018-214260.
- 110. Lee, A.S., Lee, J.S., He, Z., and Ryu, J.H. (2020). Reflux-Aspiration in Chronic Lung Disease.
 Ann Am Thorac Soc 17, 155-164. 10.1513/AnnalsATS.201906-427CME.
- 111. Savarino, E., Bazzica, M., Zentilin, P., Pohl, D., Parodi, A., Cittadini, G., Negrini, S., Indiveri, F.,
 Tutuian, R., Savarino, V., and Ghio, M. (2009). Gastroesophageal reflux and pulmonary fibrosis in
 scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med *179*, 408-413.
 10.1164/rccm.200808-1359OC.
- 112. Conboy, C.M., Spyrou, C., Thorne, N.P., Wade, E.J., Barbosa-Morais, N.L., Wilson, M.D.,
 Bhattacharjee, A., Young, R.A., Tavare, S., Lees, J.A., and Odom, D.T. (2007). Cell cycle genes are

- the evolutionarily conserved targets of the E2F4 transcription factor. PLoS One 2, e1061.
 10.1371/journal.pone.0001061.
- 938 113. Garcia-Gutierrez, L., Delgado, M.D., and Leon, J. (2019). MYC Oncogene Contributions to
 939 Release of Cell Cycle Brakes. Genes (Basel) 10. 10.3390/genes10030244.
- 114. Lastra, D., Escoll, M., and Cuadrado, A. (2022). Transcription Factor NRF2 Participates in Cell
 Cycle Progression at the Level of G1/S and Mitotic Checkpoints. Antioxidants (Basel) 11.
 10.3390/antiox11050946.
- 943 115. Portal, C., Wang, Z., Scott, D.K., Wolosin, J.M., and Iomini, C. (2022). The c-Myc Oncogene
 944 Maintains Corneal Epithelial Architecture at Homeostasis, Modulates p63 Expression, and Enhances
 945 Proliferation During Tissue Repair. Invest Ophthalmol Vis Sci 63, 3. 10.1167/iovs.63.2.3.
- Wruck, C.J., Wruck, A., Brandenburg, L.O., Kadyrov, M., Tohidnezhad, M., and Pufe, T. (2011).
 Impact of Nrf2 on esophagus epithelium cornification. Int J Dermatol 50, 1362-1365. 10.1111/j.13654632.2011.04989.x.
- Jones, R., Junghard, O., Dent, J., Vakil, N., Halling, K., Wernersson, B., and Lind, T. (2009).
 Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux
- 951 disease in primary care. Aliment Pharmacol Ther *30*, 1030-1038. 10.1111/j.1365-2036.2009.04142.x.
- 952

953 FIGURES

Figure 1. ScRNA-seq sample composition by cell type. A) Integrated UMAP embedding of all cells
 (n=306,372) labeled by cell type. B) Expression by cell type of canonical markers. C) Sample-wise (n=39)
 distribution of major cell types. D) Proportion of cells by cell type.

957

958 Figure 2. Landscape of esophageal epithelial cells. A) Histological summary of the human esophageal 959 epithelium, adopted from Clevenger et al.²⁸ Alternatively shaded cells within the same layer represent 960 proliferating cells. NOTE: The layers of replicating cells not attached to the basement membrane, labeled 961 here as proliferating suprabasal cells, are sometimes referred to as epibasal cells²⁸. B) Integrated UMAP 962 embedding of all esophageal epithelial cells (EECs, n=230,720) labeled by epithelial compartment. C) 963 Expression by EEC compartment and cell cycle markers. C) Proportion of proliferating basal and 964 suprabasal cells by condition and biopsy location. E) Proportions of cells by condition, EEC compartment, 965 and biopsy location. The bars denote the mean values, the vertical lines the standard deviations, and the 966 points the individual sample proportions. Pairwise differences across conditions were evaluated statistically 967 using MASC⁵². *p<0.05; **p<0.005.

968

969 Figure 3. Distribution of esophageal epithelial cells by differentiation score and epithelial 970 compartment. A) Integrated UMAP embeddings of esophageal epithelial cells divided by disease state, 971 colored by differentiation score. B) Swarm plots of esophageal epithelial cells by differentiation score, 972 colored by epithelial compartment.

973

Figure 4. Differential gene expression at single-cell resolution in esophageal epithelial cells. A) Intersample expression correlations are shown for each epithelial compartment for the 2,000 most variable
genes. B) The distribution of inter-sample expression correlations are shown by epithelial compartment. CD) UpSet plots showing differential gene expression at the single-cell level by epithelial compartment for
SSc vs HCs (purple) and GERD vs HCs (orange) in the proximal (C) and distal (D) esophagus. E) The
number of significantly differentially expressed genes with |log₂FC| >0.1 are shown for SSC vs. HCs and
GERD vs. HCs, by non-proliferating epithelial compartment and biopsy location. F) Gene set enrichment

981 analysis results, showing all pathways enriched with P<0.001 (unadjusted) for SSc vs. HCs (purple) and 982 GERD vs. HCs (orange), split by non-proliferating epithelial compartment and biopsy location. Pathways in 983 bold had enrichment with P<0.001 in both SSc and GERD. Points circled in red indicate statistical 984 significance after adjusting for the number of tested pathways (PFDR<0.05). G-H) Relative gene expression 985 (SSc vs. HCs) for all DEGs at the single-cell level were modeled using Lamian⁶⁵ and plotted against the 986 epithelial differentiation score in the proximal (G) and distal (H) esophagus. These trajectories were 987 clustered based on Euclidean distance using Ward's method. The lefthand color bar displays the blended 988 color of all epithelial compartments in which each gene was differentially expressed. In G), labeled genes 989 highlight the top 25 ranked genes in the leading edge of the innate immune system pathway enriched in 990 SSc in the superficial compartment of the proximal esophagus. In **H**), the labeled genes mark the leading 991 edge genes of the matrisome pathway enriched in SSc in the suprabasal compartment of the distal 992 esophagus. I-L) Dot plots showing average gene expression, by condition and epithelial compartment, for 993 the most highly represented protein families in the leading edges of significantly enriched pathways: 994 keratins (I), S100 proteins (J), small proline-rich proteins (K), and serine protease inhibitors (L). M) Single-995 cell gene expression by condition, epithelial compartment, and esophageal region for PI3, the most frequent 996 gene in leading edges of significantly enriched pathways.

997

998 Figure 5. Differential gene expression aggregated by sample and EEC compartment. A-B) Gene 999 expression differences between SSc and HCs (A) and between SSc and GERD (B) are shown for each 1000 EEC compartment. Significant DEGs (FDR<0.05) are highlighted in purple. The percentages of genes that 1001 were significantly differentially expressed in each compartment are plotted in blue in along the secondary 1002 Y axis. C-D) Gene expression differences in log₂FC are shown for SSc vs. HCs (Y axis) against GERD vs. 1003 HCs (X axis) within the superficial compartment in the proximal (C) and distal (D) regions. Significant DEGs 1004 in both conditions are highlighted in blue, significant DEGs in SSC only are highlighted in purple, and 1005 significant DEGs in GERD only are highlighted in orange. The correlation between comparisons is shown 1006 in the upper left, and the slope and coefficient of determination for the modeled linear regression with 1007 intercept=0 is displayed in the lower right. Trendlines with 95% confidence intervals are plotted in pink, and 1008 the dashed grey lines denote where y=x. Encircled points highlight disease-specific DEGs that are

1009 referenced in the main text and plotted in (E), which shows the distribution of expression aggregated by 1010 sample in the superficial compartment across conditions and biopsy locations. Pairwise differential 1011 expression was determined using edgeR's guasi-likelihood F-tests: *p<0.05; **p<0.05; ***p<0.0005. F) The 1012 number of significant DEGs are shown for GERD vs. HCs (orange) and for all permutations of n=4 samples 1013 for SSc vs. HCs (purple) in superficial cells for both proximal and distal regions. The point within the SSc 1014 distribution is the median value. G-H) The distributions of relative FC or slope m (G) and coefficient of 1015 determination r^2 (H) are shown for all permutations of n=4 SSc samples, determined by modeling a linear 1016 regression with intercept=0 for the log₂FC of SSc vs. HCs against the log₂FC of GERD vs. HCs for all 1017 expressed genes in the superficial compartment for both proximal and distal regions. DEG, differentially 1018 expressed gene; FC, fold change.

1019

1020 Figure 6. Landscape of superficial esophageal epithelial cells. A) Integrated UMAP embedding of all 1021 superficial EECs (n=30,866) clustered by unique transcriptional signatures. B) Relative expression of 1022 cluster-specific gene signatures. C) Epithelial differentiation score by superficial cell cluster. D) Proportion 1023 of superficial cells by condition and cluster from the proximal esophagus. The bars denote the mean values, 1024 the vertical lines the standard deviations, and the points the individual sample proportions. Pairwise 1025 differences across conditions were evaluated statistically using MASC⁵². *p<0.05; **p<0.005. E) Distribution 1026 of metallothionein module score in proximal, superficial cells by condition. The metallothionein module 1027 score included MT1A, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, and MT2A. F) Distribution of relative 1028 metallothionein expression by cluster and condition in superficial cells from proximal esophagus. All 1029 pairwise comparisons were between SSc and GERD were statistically significant, except for cluster 5.

1030

Figure 7. Expression of enriched transcription factors and their targets in superficial EECs in proximal esophagus. The distributions of enriched transcription factor expression and target module scores are shown proximal, superficial cells by condition and superficial cluster for A) IRF1, B) MYC, C) E2F4, and D) NE2L2.

1035

35

1036 Figure 8. Correlations with clinical phenotypes. A) Heatmap of quantitative clinical traits organized using 1037 agglomerative, complete hierarchical clustering on Euclidean distances, with pairwise Spearman 1038 correlations shown in each cell. B) SSc cases are plotted on the first two PCs of the quantitative clinical 1039 traits, colored by esophageal motility phenotype. The relative magnitude and direction of trait correlations 1040 with the PCs are shown with black arrows. C) Correlations between EEC compartments and clinical trait 1041 PCs in SSc cases. Linear regression trendlines with 95% confidence intervals are shown for each 1042 compartment against PC1 and PC2. D) Correlations between aggregate, relative metallothionein 1043 expression and clinical trait PCs in superficial cells in the proximal esophagus. Trendlines with 95% 1044 confidence intervals are shown with the unadjusted correlation P-value. The metallothionein module score 1045 included MT1A, MT1E, MT1F, MT1G, MT1H, MT1M, MT1X, and MT2A. E) Correlations between superficial 1046 clusters (SCs) and clinical trait PC1 in SSc cases. Linear regression trendlines with 95% confidence 1047 intervals are shown for each SC. The displayed P-values correspond to the highlighted correlations 1048 between SC3 and PC1. F) Boxplots showing the proportion of SC3 in superficial cells by esophageal motility 1049 phenotype in the proximal and distal esophagus, colored by disease state (HCs, grey; GERD, orange; SSc, 1050 purple). AET, acid exposure time; BEDQ, brief esophageal dysphagia questionnaire; BMI, body mass index; 1051 DCI, distal contractile integral; DI, distensibility index; EGJ, esophagogastric junction; EGJOO, 1052 esophagogastric junction outflow obstruction; FLIP, functional luminal imaging probe panometry; HCs, 1053 healthy controls; HRM, high-resolution manometry; IEM, ineffective esophageal motility; IQR, inter-quartile 1054 range; IRP, integrated relaxation pressure; NEQOL, Northwestern esophageal quality of life; NM, 1055 neuromyogenic model. NR, not reported.

1056 SUPPLEMENTAL FIGURES

1057 Supplemental Figure 1. Cell clustering and cell type annotation. A) Cell type module scores for 10 1058 detected cell types, colored by relative gene expression of the listed genes. B) Projected UMAP 1059 embeddings calculated on the top 40 PCs with n=200 neighbors. Cells are colored by cluster, which are 1060 numbered in descending order by total cell count. Clusters were determined using Seurat's modularity-1061 based clustering on a shared nearest neighbor (SNN) graph with k=25 and resolution=0.25 on the top 40 1062 PCs. C) Isolation of cluster 13 for annotation of cell types with smaller proportions of cells and projected 1063 UMAP embeddings for cluster 13, colored by subcluster. D) Cell type module scores for 7 detected cell 1064 types in subcluster 13, colored by relative gene expression of the listed genes.

1065

1066 Supplemental Figure 2. Epithelial cell quality control and annotation. A) Projected UMAP embeddings 1067 for integrated, esophageal epithelial cells (EECs) calculated on the top 35 PCs with n=100 neighbors. Cells 1068 are colored by cluster, which are numbered in descending order by total cell count. Clusters were 1069 determined using Seurat's modularity-based clustering on a shared nearest neighbor (SNN) graph with 1070 k=40 and resolution=0.50 on the top 40 PCs. B) EEC UMAP projection, colored by the number of unique 1071 genes per cell. C) Distribution of number of UMIs detected per cell, split by cluster. EECs with <3500 1072 UMIs/cell were removed from further analysis. D) EEC UMAPs colored by gene expression (log(counts+1))) 1073 for genes included in compartment-specific expression scores, E) EEC UMAPs colored by compartment 1074 expression scores. F) Projected UMAP embeddings for post-guality-control EECs calculated on the top 35 1075 PCs with n=100 neighbors. Cells are colored by cluster, which are numbered in descending order by total 1076 cell count. Clusters were determined using Seurat's modularity-based clustering on a SNN graph with k=50 1077 and resolution=0.25 on the top 35 PCs. G) Result of K-means clustering to distinguish suprabasal from 1078 basal cells, based on expression of corresponding cluster markers (Supplemental Figure 4) in clusters 3, 1079 4, and 5, with K=2. H) Result of K-means clustering to distinguish superficial from suprabasal cells, based 1080 on expression of corresponding cluster markers (Supplemental Figure 4) in clusters 6, 7, and 8, with K=2. 1081 I) Predicted classification of cell cycle state in EECs determined using using Seurat's CellCycleScoring() 1082 function.

1083

1084 **Supplemental Figure 3. Derivation of epithelial cell differentiation score. A)** Density plots of 1085 esophageal epithelial cell compartment module scores by compartment annotation. **B)** Density plot of 1086 epithelial cell differentiation score by annotated compartment. **C)** UMAP of esophageal epithelial cells 1087 colored by differentiation score.

1088

Supplemental Figure 4. Group-wise gene expression correlation for variable genes. A) 2,000 most variable genes among single cells across all samples, with top 20 labeled. B) Correlations of gene expression aggregated by condition and biopsy location are shown for each epithelial compartment for the 2,000 most variable genes, with proximal samples along the Y axis and distal samples along the X axis.

1093

1094 Supplemental Figure 5. Differential gene expression aggregated by sample and esophageal 1095 epithelial cell compartment. A) Multidimensional scaling plots of aggregate gene expression samples 1096 colored by sample, epithelial compartment, condition, and biopsy location. B) Volcano plots of differential 1097 gene expression between SSc and GERD by epithelial compartment and biopsy location with significant 1098 associations highlighted in red and outer significantly differentially expressed genes labeled. C) Gene 1099 expression differences in log₂FC are shown for SSc vs. HCs (Y axis) against GERD vs. HCs (X axis) for 1100 each epithelial compartment in the proximal and distal regions. Outer significantly differentially expressed 1101 genes are labeled, as well as immune-related genes uniquely differentially expressed in SSc. The 1102 Spearman correlations between gene expression differences are shown in the upper right of each plot (r). 1103 the relative FC or slope (m) and coefficient of determination (r^2) are shown in the bottom right of each plot. 1104 Trendlines with 95% confidence intervals are plotted in pink, and the dashed grey lines denote where y=x. 1105 D) Distributions of aggregate gene expression by epithelial layer, biopsy location, and condition are shown 1106 for top SSc-specific and GERD-specific differentially expressed genes.

1107

1108 **Supplemental Figure 6. Expression of superficial esophageal epithelial cell markers.** UMAPs with 1109 expression for the top superficial cluster markers are shown along with the epithelial differentiation score 1110 for superficial cells.

1111

38

Supplemental Figure 7. *FLI1* expression in human esophageal mucosa. A) UMAP of integrated mucosal dataset, colored by *FLI1* expression. The distribution of *FLI1* expression by cell type is shown in the upper right. B) Distribution of *FLI1* expression by cell type and disease state. Endothelial cells had the highest *FLI1* expression, but the expression differences between diseases was not significant. C) Violin plot of the relative expression of FLI1 target genes in superficial cells.

1117

1118 Supplemental Figure 8. Epithelial cell compartment proportions and additional correlations by 1119 motility phenotype. A-B) Proportions of esophageal epithelial cell compartments by HRM (A) and FLIP 1120 (B) esophageal dysmotility phenotypes are shown for the proximal and distal esophagus samples. The 1121 bars denote the mean values, the vertical lines the standard deviations, and the points the individual 1122 sample proportions. C) The relationship between the proportion of superficial cells and the SSc disease 1123 duration is plotted for proximal and distal samples. Trendlines with 95% confidence intervals are plotted in 1124 pink, and correlation P-values are displayed in the upper right corners. D) The distribution of normalized 1125 gene expression values by esophageal motility phenotype are shown for the TRIM11 gene for the FLIP, 1126 HRM, and NM esophogeal dysmotility classifications. Unadjusted ordinal regression p-values are 1127 displayed in the upper left corners. TRIM11 was the most strongly association gene with the dysmotility 1128 phenotypes by p-value. HRM, high-resolution manometry; FLIP, functional luminal imaging probe 1129 panometry; IEM, ineffective esophageal motility; EGJOO, esophagogastric junction outflow obstruction; 1130 NM, neuromyogenic model.

1131 **TABLES**

Table 1. Patient demographics and clinical characteristics

	HCs			SSc		GERD	
Demographics	N = 6			N = 10		N = 4	
Sex – female	5 (83.3%)			9 (90%)		3 (75%)	
Race – white		5 (83.3%)	Ì	8 (80%)		2 (50%)	
Ethnicity – non-Hispanic		5 (83.3%)		8 (80%)		2 (50%)	
Race/ethnicity – unknown/NR		1 (16.7%)		2 (20%)	2 (50%)		
Traits	Ν	Median (IQR)	N	Median (IQR)	N	Median (IQR)	
Age (yrs)	6	27 (25-29)	10	54 (47-70)	4	42 (30-56)	
BMI (kg/m ²)	6	23 (22-25)	10	22 (19-30)	4	24 (23-36)	
Esophageal motility							
Mean DCI (mmHg•s•cm)	6	464.2 (386-6-1026.1)	10	57.5 (0.0-206.1)	2	509.6 (367.4-651.7)	
Pressure 60ml (mmHg)	6	43.5 (38.3-54.5)	9	31.0 (30.5-40.3)	0	-	
EGJ barrier function							
End-expiratory EGJ pressure (mmHg)	6	7 (4-8)	10	6 (3-10)	2	12 (11-12)	
EGJ contractile index (mmHg•cm)	6	19.4 (15.2-29.0)	10	21.0 (19.1-27.5)	2	19.0 (10.8-27.1)	
Median IRP (mmHg)	6	4 (3-9)	10	6 (4-12)	2	8 (6-9)	
EGJ-DI (mm ² /mmHg)	6	6.2 (5.2-8.5)	9	6.3 (4.1-9.2)	-	-	
Reflux severity							
AET (%)	6	0.8 (0.5-2.8)	4	8.7 (3.3-14.5)	3	16.8 (13.9-17.3)	
GerdQ ¹¹⁷ score	6	0 (0-0)	10	3 (1-4)	3	3 (3-4)	
BEDQ ³⁹ score	6	0 (0-0)	8	8 (3-14)	3	1 (1-1)	
NEQOL ⁴⁰ score	6	56 (56-56)	8	31 (23-47)	3	36 (29-46)	

1132 AET, acid exposure time; BEDQ, brief esophageal dysphagia questionnaire; BMI, body mass index; DCI, distal contractile integral;

1133 DI, distensibility index; EGJ, esophagogastric junction; HCs, healthy controls; IQR, inter-quartile range; IRP, integrated relaxation

1134 pressure; NEQOL, Northwestern esophageal quality of life; NR, not reported

1135

Comparison	TF	Direction	DEG Targets	DEG Targets / DEGs	TF Targets / Background	\mathbf{P}_{adj}	TF Expr. LogFC	TF Expr. P _{adj}
SSc vs. GERD	IRF1	+/-	7	0.11	0.03	2.9×10 ⁻²	0.22	9.0×10 ⁻¹
		-	5	0.19	0.03	8.9×10 ⁻³		
	MYC	+	120	0.10	0.06	2.1×10 ⁻⁷	1.64	7.8×10 ⁻⁵
SSc vs. HCs	E2F4	+	116	0.08	0.06	5.5×10 ⁻⁵	0.88	9.8×10 ⁻⁴
	NFE2L2	-	108	0.11	0.07	7.6×10 ⁻⁴	0.25	3.2×10 ⁻¹

Table 2. Pairwise transcription factor enrichment in superficial cells in proximal esophagus

DEG, differentially expressed gene; Expr., expression; GERD, gastroesophageal reflux disease; HCs, healthy controls; LogFC, log₂ (fold change); SSc, systemic sclerosis; TF, transcription factor.

1136





















Proliferating basal Basal Proliferating suprabasal

Suprabasal Superficial

Proximal

Distal

0.5

- 0.4

0.3 0.2

0.1

0.0

0.5 0.4

0.3

0.2

0.1

0.0

- 0.5

- 0.4

0.3

0.2

0.1

0.0

Absent

Proportion out of Superficial EECs



Ε





UMAP 1

UMAP 1

UMAP 1

UMAP 1















HCs GERD SSc HCs GERD SSc HCs GERD SSc





HCs GERD SSc HCs GERD SSc HCs GERD SSc

G







	Proximal			Distal			
PTGES HC 4 - 2 - 		SSc		GERD	SSc ∳₽₽₽₽ •		
MFGE8 HC 4 - 2 - 0 - -2 -	GERD ÷ [■] ≑ ⊖	SSc ➡ ➡ च च च च च च च च च च च च च		GERD ➡ ➡ = = = = = = = = = = = = = = = = = =	SSc ≜≑≑ ₽		
FCGBP				GERD	SSc ⊨ ⇒ • • •		
10.0 7.5 5.0 2.5 0.0 -2.5							
HC 7.5 - 5.0 - 2.5 - 0.0 - APOBE	GERD GERD	SSc 쿠루구루	HC	GERD	SSc ⇒ = + ÷ ₽		
7.5 - HC 5.0 - 2.5 - .0.0 - -2.5 - C10orf9		SSc SSc SSc SSc SSc SSc SSc		GERD ↓ ↓ ↓ ↓ ↓			
	GERD			GERD	SSc		
 5.0 - 2.5 - 0.0 - -2.5 - ACKR3	GERD	SSc		GERD	SSc ₱₽ [₽] ₽ ₽		
6 - 4 - 2 - 0 - -2 - -4 -	GERD · · ÷ ÷ ÷ ÷	SSc		GERD	SSc ♥╤ ↓↓ ↓ ↓		
FILA-B HC 10.0 - 7.5 - 5.0 -	GERD ≜≐≟÷		нс - - - - - - - - - - - - - - - - - - -	GERD ≠≞⊜ _⊖ ⊢	SSc		
HC 10.0 - 7.5 - 5.0 - 2.5 - 0.0 - TAP1		SSc SSc			SSc		
5.0 - 2.5 - 0.0 - -2.5 -	GERD ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓		HC 	GERD	SSc ≑≑≑ _∳ ∳		
7.5	GERD +÷≑≑ ∳	SSc SSc		GERD ÷ [⇒] ⇒ ⇒	SSc ≑÷÷÷ ₽		
- - +C ₅ _ + ÷ _		SSc ∳₹₽ ↓ ↓	нс _==== ==	GERD ■=== == ==	SSc ÷÷÷ ÷		

D



	Distal	
HC	GERD	SS
	∙≠∳↓ ₽	
	GERD ≑∃ [≑] ≑	ss ↓↓↓ ₽
НС	GERD	SS



GERD

÷÷

÷ ==

• •

. . ₽



SSc

























₽ ₽ ₽ ₽ ₽	⊨≓≓≓ ⊷ ₽ ∙	¢¢¢¢ ₽	╴ ╡ ╡
SGK1 нс	GERD	SSc ↓↓↓↓	- - -
HBEGF	+		
HC ➡ ➡ ➡ ➡ ➡ ➡	GERD ⇒ → ⇒ ·	SSc	- - - - -
<i>МТ1А</i> нс	GERD	SSc	нс
■ ■ □ □	₽ ¢¢¢¢	≜⇔ _⇔ .	╴ ╴ <mark>흦</mark> ᇦᇢᇦ
MT1E нс	GERD	SSc	НС
₽₽₽ ₽	₽₽⊖ ₽	≜≑ _¢ ∙ ¢	- ⇒÷≑
<i>МТ1F</i> нс	GERD	SSc	НС
*	** <u>.</u>	÷÷⇔	- - - - +
МТ1G нс	GERD	SSc	НС
			- - ∳ ^{₽₽} ₽
<i>МТ1Н</i> нс	GERD	SSc	НС
	₽ P [₽] ₽	, ≞÷. , ,	- •≠ [‡] ₽
<i>МТ1М</i> нс	GERD	SSc	НС
÷÷¢ţ	••: •	+÷	╴ ╴ ╸ [╪] ╞ _╞
МТ1Х нс	GERD	SSc	НС
	·= ₽		╴ ╴╞╡・ ╴
<i>МТ2А</i> нс	GERD	SSc	НС
<u>.</u>	• [≠] • [●]	∔÷÷. ≢	- - ÷ ≑¢ -
H19 нс	GERD	SSc	НС
÷ ÷ ¢	⊨≓ [†]	<u>↓</u> ↓↓↓	
<i>MUC22</i> нс	GERD	SSc	НС
ŧ			-
SLC8A1-A	_≟≟÷ 4 <i>S1</i>		





















12 -



8 -0 —













































































Normal Impaired/ Absent Diminished Normal Ineffective Absent

Normal Ineffective Absent